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Abstract
The intracellular delivery of therapeutic biomolecules such as oligonucleotides and pro-
teins remains a key challenge today. Protective antigen, a naturally evolved protein translocase
derived from Bacillus anthracis, has shown promise as a platform of protein delivery due to its
ability to form a transmembrane pore that allows the cargo to have cytosolic access. We and others
have used the LFN/PA system to deliver a wide variety of natural and non-natural peptides and
proteins.
Despite the significant progress made with the LFN/PA delivery platform, some aspects
including cargo selection and targeting still remain limited. In the first part of the thesis, we greatly
expand the application of the platform by demonstration of efficient delivery of peptide nucleic
acids (PNAs), an oligonucleotide analog. Using this technology, we successfully exploited a can-
cer-specific gene dependency by the intracellular delivery of an anti-sense PNA in a receptor-
dependent manner.
In addition to exploiting new types of cargo for delivery, we developed a new strategy to
target the LFN/PA system to specific cell types. In the second part of the thesis, we chemically
conjugated a full-length immunoglobulin G (IgG) to a mutant PA (mPA). Significantly, we took
advantage of the fact that PA activation is protease-dependent and created highly specific delivery
vehicles that can only be activated by the concurrent presence of two entities on the cell surface.
We showed a protein toxin delivered by these IgG-mPA variants effectively inhibited cell growth
in different cancer cell lines and exhibited a significantly increased therapeutic window over pre-
viously reported PA variants both in vitro and in vivo.
In the last part of the thesis, we explored the possibility of simplifying the LFN/PA system
by directly ligating protein cargos to PA. In the absence of LFN, the chemically created single-
component system significantly increased the amount of delivered cargo. Moreover, the single-
component system combined with a short N-terminal polylysine tag further improved the delivery
efficiency by more than 100-fold. Our findings raise the prospect of a simpler PA-mediated deliv-
ery platform.
Thesis Supervisor: Bradley L. Pentelute
Pfizer-Laubach Career Development Professor of Chemistry
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Scope of Thesis
This thesis aims to develop novel strategies to improve different aspects of the protective
antigen-mediated delivery, including cargo selection, targeting, and overall complexity.
Chapter 1 reports the delivery of a class of anti-sense oligonucleotide using the LFN/PA
system to target cancer cells. Delivery of therapeutic oligonucleotides into cells remains a major
challenge. We studied protective antigen (PA), a component of anthrax toxin, as a non-viral, lipid-
free delivery platform for peptide nucleic acids (PNAs). PNAs are versatile agents used to perturb
different processes in the cytosol of cells. PNAs of different lengths and sequences were covalently
linked to the 263-residue N-terminal domain of lethal factor (LFN) via sortase-mediated ligation.
We found the LFN/PA system was able to transport all PNAs under study efficiently into the cyto-
sol of mammalian cells. Furthermore, using this technology we successfully exploited a cancer-
specific dependency on SF3B1. Over 10% of cancers have lost one or more copies of SF3B1,
which renders these cancers susceptible to further SF3B 1 suppression. This dependency on SF3B 1
is one example of a class of over 120 CYCLOPS (Copy number alterations Yielding Cancer Lia-
bilities Owing to Partial losS) dependencies in cancer. Anti-sense PNAs delivered by the LFN/PA
system suppressed SF3B 1 expression and reduced cell viability of cancer cells with partial copy-
loss of SF3B 1, but not cells without SF3B 1 loss. Moreover, PNA was delivered selectively to a
HER2-overexpressing cancer cell line using a HER2-binding PA variant, demonstrating cell type-
specific targeting. We conclude that our PA-mediated delivery system is a powerful tool for oli-
gonucleotide-based antisense technologies and provides a potentially generalizable approach to
target SF3B 1 and dozens of other dependencies in cancer.
Chapter 2 describes a novel and widely applicable strategy to target the LFN/PA delivery
system to specific cell types of interest. Immunoglobulin G (IgG) is currently one of the most
16
important classes of therapeutics. Due to its wide application and favorable in vivo properties,
there has been significant interest in using IgG as a drug carrier. Although some success has been
achieved with small molecules and self-translocating protein toxins, the antibody-mediated deliv-
ery of the majority of proteins has been elusive. Here, we report a targeted protein delivery system
by chemically conjugating a mutant protein translocase mPA to an IgG molecule. Using this sys-
tem, we demonstrated the delivery of different protein cargos by different antibodies and overcame
antibody drug resistance in refractory cancer cell lines. Significantly, we took advantage of the
fact that PA activation is protease-dependent and created highly specific delivery vehicles that can
only be activated by the concurrent presence of two entities on cell surface. We showed that a
protein toxin delivered by these IgG-mPA variants had a significantly increased therapeutic win-
dow and effectively inhibited tumor growth both in vitro and in vivo.
Chapter 3 reports a novel single-component PA-mediated delivery system. Anthrax toxin
is a tripartite toxin derived from Bacillus anthracis. The effector proteins lethal factor (LF) and
edema factor (EF) are delivered into the cytoplasm of cells by protective antigen (PA). It has been
shown that the N-terminal region of LF (LFN) is capable of PA-dependent translocation. Here we
report a single-component PA-mediated delivery system by chemically conjugating the cargo pro-
tein to PA. We showed that, in the absence of LFN, the single-component approach can signifi-
cantly increase the amount of delivered cargo. Moreover, we discovered that, when combined with
a short N-terminal polylysine tag, the single-component system improved the delivery efficiency
by more than 100-fold. Our findings raise the possibility of a simpler PA-mediated delivery plat-
form.
17
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Chapter 1: Targeting cancer gene dependencies via anthrax-mediated
delivery of peptide nucleic acids
Author Contributions
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peptides, and proteins and performed the PNA translocation assays and some of the cell viability
assays; Brenton R. Paollela, Meredith S. Brown, and John Busanovich performed western blot and
some of the cell viability assays; Zeyu Lu and Brenton R. Paollela wrote the manuscript with input
from Rameen Beroukhim and Bradley L. Pentelute.
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1.1. Introduction
Due to their affinity and specificity for RNA and DNA targets, therapeutic oligonucleotides
are promising drug candidates for a wide range of diseases including cancer, Alzheimer's and
cardiovascular disorders'. Peptide nucleic acids (PNAs) are nucleic acid analogs in which the
sugar-phosphate backbone is replaced by N-(2-aminoethyl)glycine units2. PNAs form strong
complexes with complementary strands of DNA or RNA and, due to their pseudopeptide backbone,
are not degraded by nucleases or proteases, thus making PNAs attractive candidates for antisense
and anti-gene therapeutics 4 .
One set of attractive therapeutic targets for PNAs are CYCLOPS (Copy number alterations
Yielding Cancer Liabilities Owing to Partial losS) genes. CYCLOPS genes are cell-essential genes
that often undergo partial copy-number loss in cancer cells. This partial copy-number loss leaves
the cancer cells with lower expression of the gene relative to normal cells, generating a therapeutic
window whereby further partial suppression of the gene can kill the cancer cells while leaving
normal cells intact. We have identified 124 candidate CYCLOPS genes; a typical cancer will
exhibit partial loss of up to 47 such genes, suggesting these may be a rich source of potential
therapeutic targets5' . These features of CYCLOPS genes-their abundance and the sensitivity of
cancers to their partial suppression-render CYCLOPS genes ideal targets for PNA therapeutics.
However, the uncharged PNA molecules are difficult to deliver across biological barriers
such as the endosomal and plasma membranes. Various protocols such as co-transfection with
DNA, microinjection, conjugation to peptides and electroporation have been devised, but none
have been met with major success7.
Fortunately, nature has evolved mechanisms to transport biomolecules into cells across
these biological barriers8 . One delivery system is anthrax toxin from Bacillus anthracis, a three-
20
component system containing the receptor-binding, pore-forming protein protective antigen (PA)
as well as the enzymatic moieties lethal factor (LF) and edema factor (EF). PA83 binds to receptors
on host cells and is cleaved by furin-family protease9 . The resulting fragment (PA 63) self-assembles
into the ring-shaped heptameric or octameric pre-pore, 0"'" forming complexes with LF and EF
with high affinity. The complexes are then endocytosed and acidification triggers conformational
rearrangement of the PA pre-pore to form an ion-conductive B-barrel transmembrane pore . LF
and EF then translocate through the PA pore into the cytosol from N- to C-terminus.
This anthrax toxin system has been disarmed by removal of the C-terminal catalytic lobes
13,14of LF and subsequently used for delivery of proteins and other variants into cells'. Often cargo
is covalently fused to the C-terminus of LFN and in the presence of PA hitches a ride through the
transporter formed in the endosome.
While the LFN/PA system has been shown to transport various polypeptide cargo attached
to the C-terminus of LFN into mammalian cells'5,1 6, here we show for the first time the successful
intracellular delivery of PNAs using LFN/PA. Furthermore, we demonstrate the utility of the
LFN/PA system to effectively target a CYCLOPS dependency on SF3B 1, an essential spliceosome
component that undergoes partial loss in 11% of all cancers
(https://portals.broadinstitute.org/tcga/home).
21
1.2. Results
1.2.1. Many cancer gene dependencies cannot be targeted using existing small molecules
To understand the general scale and features of candidate therapeutic targets in cancer, we
integrated data describing the level of essentiality of 5711 genes from an shRNA screen across 216
cancer cell lines' 7 , with genome-wide genetic profiles of these cell lines (Figure 1.2.la). We call
genes that are essential in a particular cell "gene dependencies" for that cell. We hypothesized that
gene dependencies that are only present in cells with specific somatic genetic alterations represent
candidate cancer-specific dependencies, because normal cells would not share these genetic
alterations. As cancer-specific dependencies, we therefore consider these genes to be potential
therapeutic targets in cancer.
We identified gene dependencies associated with either mutations in six known driver
genes (KRAS, PIK3CA, BRAF, NRAS, CTNNB] and EGFR) or with any copy-number alteration
genome-wide. Mutations in five of the six driver genes (with the exception of EGFR) were
associated with increased dependence on that driver; we also identified 342 additional gene
dependencies associated with mutations in these driver genes. We previously identified 174
dependencies associated with copy-number alterations, that were previously published 6. These
dependencies include 124 CYCLOPS dependencies on genes that have undergone partial loss and
50 additional dependencies on genes that were in most cases not themselves altered by the copy-
number change. Integration of the mutation and copy number associated dependencies from our
previous work yielded 486 unique context-specific gene dependencies, comprising 8% of all genes
analyzed.
We found that the vast majority (87%) of these candidate cancer gene dependencies do not
belong to a straightforward "druggable" protein target classes. We classified each gene dependency
22
by its protein target class using the IUPHAR drug targets and family database
(http://www.guidetopharmacology.org/targets.isp). Of the 486 context-specific gene
dependencies, 423 were not classified as belonging to a protein family that could be targeted by a
small molecule (Figure 1.2.1 b). On average, each cell line had 12.7 dependencies that were in an
existing IUPHAR druggable target class and 82.1 dependencies that were not (Figure 1.2.1 c, p< 10
15). These data suggest that a substantial fraction of all gene dependencies would benefit from
alternative and generalizable approaches to target cancer vulnerabilities.
Antisense gene suppression represents one tractable approach to target cancer gene
dependencies, but methods for delivery of such molecules remain limited. PNAs are stable
molecules with the capacity to suppress gene translation or transcription. However, PNAs cannot
cross cell membranes on their own. We investigated whether we could overcome obstacles to anti-
sense PNA delivery by the LFN/PA platform to enable their uptake into cells.
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Figure 1.2.1. Many cancer gene dependencies are challenging to target with existing
therapeutic approaches. a) Schematic describing our approach to detect context-specific cancer
gene dependencies. b) Pie chart indicating the IUPAR target classification for the 486 cancer gene
dependencies identified. c) Violin plot quantitating the number of potent gene dependencies per
cell line. Candidate gene dependencies that belonged to an existing IUPHAR target class were
considered "druggable". Width of plots represents relative sample density, dots represent sample
median.
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1.2.2. Protective antigen efficiently delivers PNAs of different lengths
We investigated the delivery of various PNA constructs into the cytosol of mammalian cells
using the LFN/PA system (Figure 1.2.2a). First, we synthesized a panel of PNAs of different lengths
(Figure 1.2.2b). Each PNA was conjugated to the C-terminus of LFN-DTA or LFN using sortase-
mediated ligation' 8 to give LFN-DTA-PNA or LFN-PNA conjugates (LDP or LP respectively;
Figures 1.7.1-2). DTA is the A chain of diphtheria toxin that catalyzes the ADP-ribosylation of
elongation factor 2 and inhibits protein synthesis.
We investigated the translocation efficiency of LFN-DTA conjugates using a protein
synthesis inhibition assay19 ,2 0. CHO-Ki cells were incubated with serial dilutions of purified
LDP1-9 conjugates in the presence of 20 nM of PA for 2 hours and then incubated with 3H-Leu
medium. 3H-Leu incorporation within proteins indicated the translocation efficiency of cytosolic
LFN-DTA-PNA conjugates. We found that all PNA cargo translocated in the presence of PA,
regardless of PNA length and sequence (Figure 1.2.2c). We further verified that the LDPs
translocated via the LFN/PA mechanism using controls that disrupt cellular entry. Cells treated with
LDP9 in the presence of PA[F427H], a PA mutant that arrests translocation in the endosome21 2 2 or
Bafilomycin Al, an inhibitor of endosomal acidification, did not show any protein synthesis
inhibition, indicating a functional PA and an acidic endosome are essential for translocation. After
confirming translocation, we then proceeded to work with conjugates containing only LFN, as the
toxic protein DTA was removed to eliminate any interference with normal cellular functions.
We further investigated the delivery of the PNA conjugates by Western blot. HEK-293T
cells were incubated with 250 nM of LP9 or a scrambled version of LP9 in the presence of PA for
12 hours. We collected the cytosolic lysates using digitonin as described before23 and
immunostained for the early endosome marker, Rab5, and cytosolic marker, Erkl/2 to confirm
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cytosolic extraction. Western blots indicated cytosolic delivery of LP9 and its variant (Figures
1.2.2d and 1.7.4). The band intensity of LP9 was comparable to 5 ng of purified wild-type LFN,
indicating efficient cytosolic translocation. We observed a linear relationship between protein
concentration and anti-LF staining intensity (Figure 1.7.5), and estimated a total of 3.0 ng of LP9
was delivered to 1 million cells, resulting in 51,000 molecules per cell or 84 nM cytosolic
concentration. Additionally, the molecular mass shift observed for LP9 compared to LFN indicates
the PNA cargo was intact. In order to confirm most of the delivered protein was in the cytosol, we
lysed the cells by total lysis buffer containing 1% NP-40. As expected, a similar amount of LP9
was observed in the cytosolic fraction and total cell lysate, indicating efficient translocation of LFN
conjugates from the endosome into the cytosol. As predicted, delivery with PA[F427H] did not
allow for LP9 delivery, indicating the translocation process requires a functional PA. In addition
to LP9, all LDP constructs studied were also subjected to western blot and showed similar results
(Figure 1.7.6). As an additional control, Bafilomycin Al, an inhibitor of endosomal acidification,
was used to validate the translocation pathway. These findings show that the LFN/PA translocation
system can be used as a non-viral lipid-free platform to deliver various PNAs.
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Figure 1.2.2. The non-toxic LFN/PA platform can efficiently deliver PNAs of various lengths
into cells. a) Mechanism of translocation of LFN/PA system into cells. The square represents the
PNA to be delivered. b) Peptide nucleic acids 1-9 from N-terminus to C-terminus. All PNAs have
N-terminal Gly5 tags. PNA9 is a 13-mer molecule used as a model to evaluate endosomal
translocation. c) Protein synthesis inhibition assay using CHO-Ki cells treated with varying
concentrations of LDP1-9 in the presence of 20 nM PA. After the treatment, the uptake of 3H-
Leucine is measured by scintillation counter to determine the level of protein synthesis inhibition.
The radioactive counts were normalized to cells treated with only PA. PA[F427H] is a PA mutant
that is incapable of translocation. Bafilomycin Al is a compound that inhibits endosomal
acidification. d) Western blot showing the translocation of LP9. HEK-293T cells were treated with
250 nM of LP9 and 40 nM of PA or PA[F427H] for 12 hours. The cells were subsequently subjected
to digitonin extraction or total lysis (-1 million cells per lane). Purified LP was also run on the gel
for the purpose of quantification.
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1.2.3. Anthrax-delivered PNAs effectively exploit cancer cell dependencies
We next evaluated the ability of the LFN/PA PNA system to target CYCLOPS cancer
vulnerabilities. We have previously identified 124 CYCLOPS genes across the genome. Cancers
that lose one or more copies of these genes are more sensitive to further suppression of that gene
compared to normal cells with two copies of the gene5 (Figure 1.2.3a). A typical cancer will exhibit
partial loss of up to 47 CYCLOPS genes, suggesting they are a rich source of potential therapeutic
targets. We have determined the mechanisms of selective vulnerability for two CYCLOPS genes,
the proteasome component PSMC2, and the splicing factor SF3BJ.
We previously generated isogenic cells differing only in their SF3B1 copy-number using
CRISPR to validate this CYCLOPS gene dependency 6. We designate cells lacking alterations in
SF3B1 copy-number as CRISPRneutral, while cells that exhibit partial SF3B1 copy-loss are
designated CRISPROPY-OSS. In both cases in which CYCLOPS vulnerabilities have been validated,
small molecules were unsuccessful in targeting activity of the gene product or the complex in
which it resides. Consistent with our previous observations 6, we found that CRISPROPY-oss cells
do not exhibit enhanced sensitivity towards splicing inhibition by Splicesostatin A24, a small
molecule that binds SF3B 1, when compared to CRISPRneutal (Figure 1.7.7). These data suggest an
unmet need for novel methods to target CYCLOPS gene dependencies that could also be expanded
to suppress the hundreds of candidate gene dependencies we identified.
We next established the SF3B1 CYCLOPS vulnerability prior to testing LFN/PA PNA
targeting of SF3B 1. We confirmed by immunoblot that SF3B 1 copy loss reduces SF3B1 protein
levels (Fig. 1.7.8). We then characterized the sensitivity of CRISPRneutral and CRISPRoPY~Oss cells
to partial SF3B1 suppression by siRNA to validate the SF3B1 CYCLOPS phenotype.
Transfections of increasing concentrations of siRNAs targeting SF3B 1, ranging from 12.5-200
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nM, resulted in dose-dependent SF3B1 mRNA suppression (Figure 1.7.9a). SF3B 1 suppression
was greater in cells with SF3B1 copy-loss because they express reduced levels of SF3B1 at
baseline. Consistent with the CYCLOPS phenotype, partial SF3BJ suppression in CRISPROPY's
cells reduced their viability at 25-100 nM siRNA concentrations, which were tolerated by
CRISPRneu tral cells (Figure 1.7.9b).
We therefore investigated whether the SF3B 1 CYCLOPS vulnerability could be exploited
by the non-viral lipid-free LFN/PA system. We synthesized LFN-PNAs complementary to SF3B 1
and characterized their abilities to bind and suppress SF3B 1 expression. We synthesized three anti-
sense SF3B 1 PNAs and one sense SF3B 1 PNA as a negative control (Figure 1.2.3b). One of the
antisense SF3B 1 PNA locations was designed to hybridize close to the start codon (Figure 1.2.3c),
which has been reported to enhance translation inhibition2 5 . The PNA that optimally suppressed
SF3B1 expression (named anti-sense SF3B1-PNA) hybridizes to the 144 position on SF3B1
(Figure 1.7.10).
We confirmed pharmacodynamic activity of anti-sense SF3B1-PNA. Anti-sense SF3B1-
PNA suppressed SF3B1 expression in both CRISPRneu traI and CRISPR'PY-"" cell lines (Figure
1.2.3d), and did so in a dose-dependent manner (Figure 1.2.3e). We also detected LFN in cellular
lysates by immunoblot, validating the mechanism of cytosolic delivery for the sense and anti-sense
SF3B1-PNAs (Figures 1.2.3e and 1.7.11).
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Figure 1.2.3. Targeting SF3B1 by anti-sense SF3B1-PNAs leads to suppression of SF3B1. a)
Schematic illustrating the CYCLOPS gene dependency concept. Normal cells express excess
amounts of an essential protein that allows them to tolerate partial gene suppression by RNAi or
PNAs. Whereas cancer cells with partial copy loss express less of the essential protein and are
sensitized to further gene suppression resulting in cell death. b) Schematic of SF3B1 PNA se-
quences synthesized and conjugated to LFN. c) Schematic illustrating the location of anti-sense
SF3B 1 PNAs on the SF3B 1 mRNA transcript. Arrowheads mark the locations of the PNAs relative
to their distance from the translational start site. d) SF3B 1 immunoblot blot demonstrating sup-
pression of SF3B1 in both CRISPRneutral and CRISPRWPyI'"ss cells by anti-SF3B1 LFN-PNAs. e)
SF3B 1 and anti-LF immunoblot in CRISPRneural cells with 8, 40, or 250 nM LFN-conjugated an-
tisense SF3B 1 PNA in the presence of 50 nM PA. 250 nM LFN-conjugated SF3B 1 sense PNA was
used as a control. Lysates were collected four days after LFN/PA PNA delivery.
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Cancer cell: copy loss
Therefore, we tested whether LFN/PA delivered anti-SF3B 1 PNAs could target the SF3B 1
CYCLOPS vulnerability and selectively kill SF3B 1's cells. CRISPReutra' and CRISPRop-YO's
cells were treated with 7-1000 nM anti-sense SF3B1-PNA in the presence of 50 nM PA, while
1000 nM of sense SF3B1-PNA treatments served as controls. CRISPROPY'-OsS cells had
significantly reduced viability upon anti-sense SF3B1-PNA/PA exposure from 125-1,000 nM that
was not observed in CRISPRneutraI cells or with sense SF3B1-PNA controls (Figures 1.2.4a-b).
These data suggest that the LFN/PA delivery platform can be used to effectively target CYCLOPS
vulnerabilities, including those that cannot be targeted with existing small molecules.
Native anthrax receptors (ANTXR1 and ANTXR2) are ubiquitously expressed across
human tissues, suggesting that LFN/PA mediated delivery of PNAs could target genetic
dependencies in many cell lines and diverse tumor types. To evaluate the general applicability of
the LFN/PA PNA delivery system, we tested anti-sense SF3B 1 suppression in nine additional cell
lines from breast and blood lineages. These cell lines represent varied cellular contexts including
adherent and non-adherent growth conditions, and molecular subtypes of cancer from unique cells
of origin.
Delivery of anti-sense SF3B1 PNAs by LFN/PA resulted in significantly reduced cell
viability in SF3Bo's cell lines with naturally occurring SF3B1 copy loss from breast and blood
cancers. SF3B 1 suppression by PNA delivery resulted in ~50% reduced viability in SF3BIl/.. cell
lines, BT549 and HCC 1954, but not SF3B1neral cell lines HS578T and MCF7 (Figure 1.2.4c). We
also observed significantly reduced cell viability upon anti-sense SF3B 1 PNA delivery in blood
cancer cell lines with SF3B 1 copy-loss (Figure 1.2.4d).
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Figure 1.2.4. Anthrax-mediated delivery of anti-sense SF3B1-PNAs induces cell death in
SF3B1'Oss cells across multiple cell types. a) Dose response curve for relative cell viability of
CRISPRneutraI (black) and CRISPR"Py-"Is (red) cells to LFN/PA mediated delivery of anti-sense
SF3B 1 PNAs. Cell viability calculated as the fold change in Cell Titer-Glo luminescence relative
to PNA only (no delivery system) control. Representative experiment performed in duplicate. b)
Viability of cells treated with LFN-conjugated SF3B1 sense in parallel experiments. c,d) Breast
and blood cell lines with SF3B 1neutral or SF3B 1 s' were treated with 100 nM of sense or antisense
LFN-SF3Bl in the presence of 50 nM wild-type PA. Viability of cells was measured by Cell Titer-
Glo and normalized to untreated cells. All experiments were performed in triplicate. For all panels
*p<0.05, **p<0.01, and ***p<0.001.
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One significant advantage of the LFN/PA system compared to other delivery systems is its
ability to target specific cell types as demonstrated by others previously. To this end, we treated
ERBB2 neutra BT549 and ERBB2 nP HCC 1954 cells with PNAs and a known chimeric PA variant
that is fused with an affibody (PA-HER2) that targets ERBB2. Although both cell lines were
sensitive to anti-sense PNA delivery by wild type PA (Figure 1.2.4c), only ERBB2an'P HCC1954
cells were susceptible to anti-sense SF3B1-PNAs delivered by PA-HER2 (Figure 1.2.5a). As
controls, PA-HER2 treatment without PNA or with sense SF3B 1 -PNA did not yield any significant
change in cell viability. Consistent with the specificity of the HER2-targeting affibody, treatment
of ERBB2neutral Cal5I-SF3BI " cells, known to be sensitive to SF3BI suppression, did not exhibit
reduced cell viability with PA-HER2 delivered anti-sense SF3B1 PNAs but did have reduced
viability when treated with wild-type PA targeted PNAs (Figure 1.2.5b). Taken together, these data
suggest that the PA system is a potent PNA delivery system that can also be readily engineered to
retarget PNA delivery to endogenous cancer cell specific receptors, such as ERBB2.
Since cell penetrating peptide (CPP)-mediated delivery of PNAs have been previously
described 26, we directly evaluated the potency of the LFN/PA system compared to a commonly
used CPP TAT. Anti-sense SF3B 1 PNA was conjugated to TAT via "click chemistry" and the
resulted conjugate TAT-PNA was purified by HPLC. SF3B1I'OSs Cal51 or HCC1954 cells were
incubated with TAT-PNA or LFN-PNA in the presence of PA or PA-HER2. Unmodified PNA was
included as a negative control. Both cell lines exhibited dose-dependent viability reduction as the
result of LFN-PNA/PA treatment and only ERBB2an'P HCC1954 showed susceptibility to LFN-
PNA/PA-HER2 treatment (Figures 1.2.5c-d), consistent with our previous observations (Figures
1.2.5a-5b). However, neither TAT-PNA nor unmodified PNA resulted in any appreciable effect on
viability up to a maximum of 5 uM. These results suggest LFN/PA system is 100- to 1000-fold
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more potent for PNA delivery than TAT-conjugated CPPs, possibly due to the interaction between
the CPP and serum and the superior ability of the LFN/PA system to release PNA from the
endosome.
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Figure 1.2.5. Cancer specific retargeting of Anthrax-mediated anti-sense SF3B1 PNAs in-
duces cell death in ERBB2 amplified breast cancer cells. a) Viability of ERBB2 neutraI BT549
and ERBB2SS HCC 1954 cells after treatment with sense or antisense LFN-SF3B 1 in the presence
of PA-HER2, a ERBB2-specific PA variant. b) Viability of ERBB2 neutral Cal5i with SF3B1IOss
after delivery of sense LFN-SF3B1 using wild-type PA or PA-HER2, non LFN-conjugated anti-
sense SF3BI PNA ("PNA only") was used as a control. c,d) Dose response curves of SF3B1loss
Cal5 1 (ERBB2neutraI) and HCC 1 954(ERBB2arnp) cells treated with antisense TAT-PNA or antisense
LFN-PNA in the presence of PA or PA-HER2. For all panels, error bars represent +-SD, *p<0.05,
**p<0.01 and ***p<0.001.
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We then determined the specificity of anti-SF3B 1 PNA delivery through a rescue
experiment. Specifically, we asked whether enhanced SF3B 1 expression could prevent the loss of
cell viability upon SF3B1 suppression. We first confirmed increased expression of SF3B 1 in
CRISPR'PyI"ss cells transfected with an SF3B 1 expression vector relative to GFP controls, in the
context of treatment with anti-sense SF3B1-PNA (Figure 1.2.6a). We then found that this
exogenous SF3B1 expression increased cell viability upon LFN/PA delivery of anti-sense SF3B 1
PNAs, relative to GFP-expressing controls (Figure 1.2.6b).
We further confirmed that anti-sense SF3B 1 -PNAs reduced viability of SF3B 1 's cells by
interfering with splicing. To this end, we quantified splicing activity using dual luciferase reporters.
One vector contained a luciferase ORF interrupted by an intron (Luc-I), which required splicing
for its function, while the second vector was a control luciferase ORF that does not require splicing
for its activity (Luc-ORF) (Figure 1.2.6c). Upon anti-sense SF3B1-PNA delivery, SF3B"" cells
had significantly decreased splicing activity compared to SF3Bneutla cells with SF3B 1
suppression (Figure 1.2.6d). We also observed a modest, but nonetheless significant, decrease in
splicing activity in SF3B 1" cells treated with antisense SF3B 1 PNAs compared to control
SF3B1 sense PNAs. These data indicate that anthrax-mediated delivery of PNAs can be used to
target the SF3B 1 CYCLOPS gene dependency.
In addition to targeting SF3B 1, I also investigated the delivery of anti-sense PNA to inhibit
telomerase as another application for this technology. Since it is not a part of the CYCLOPS work,
its information can be found in section 1.7.2.
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Figure 1.2.6. Specificity of LFN/PA mediated delivery of anti-sense SF3B1 PNAs. a) SF3Bl
immunoblot in CRISPR'"Py~'*" cells expressing either GFP or exogenous SF3B 1. Cells were sub-
sequently treated with sense or anti-sense LFN-SF3Bl PNAs in the presence of PA. b) Dose re-
sponse curve of relative cell viability in CRISPRPy~'s cells upon LFN/PA delivery of SF3Bl
PNAs expressing either GFP or exogenous SF3Bl as in (a). CRISPR"Py"ss cells with anti-sense
SF3Bl delivery expressing GFP (red) had decreased viability compared to CRISPR4~'45"O cells
with the same anti-sense PNA with enhanced SF3B 1 expression (blue). CRISP*'OPy"ss cells ex-
pressing GFP with sense targeting SF3B 1 PNAs served as a control (black). Cell viability calcu-
lated as the fold change in Cell Titer-Glo luminescence relative to PA only (no LFN-PNA) control.
Representative experiment performed in triplicate. c) Schematic of luciferase reporters used to
evaluate changes in pre-mRNA splicing. Luc-ORF contains a luciferase open reading frame that
does not require splicing for its activity. Luc-I contains a luciferase open reading frame with an
intronic sequence that requires splicing for its activity. d) Quantitation of splicing activity after
LFN/PA SF3B 1-sense (black) or SF3B1-anti-sense (red) PNA delivery. Splicing activity was quan-
tified as the ratio of Luc-I to Luc-ORF signal after normalizing to SF3Bl sense PNA as a control.
For all panels, error bars represent +-SD, *p<0.05, **p<0.0I and ***p<0.001.
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1.3. Discussion
Recent profiling of cancer gene dependencies by loss of function screens have enabled
systematic identification of candidate therapeutic targets in cancer17,2 7. However, our analyses
suggest the number of cancer gene dependencies that can be directly targeted with traditional small
molecule approaches remains limited. Therefore, substantial opportunity exists for alternative
therapeutic approaches to target the spectrum of gene dependencies identified. While many
modalities will be needed, potential therapeutic approaches that can phenocopy gene suppression
would have broad appeal.
Here we developed an anthrax-derived LFN/PA system that could efficiently deliver PNAs
into the cytosol. Our data indicate that PNAs could 'piggy back' on the C-terminus of LFN and
translocate through PA into the cytosol. The translocation efficiency was found to be independent
of the PNA length for the constructs tested, demonstrating a unique advantage of the LFN/PA
system. The PA nanomachinery is quite promiscuous and once translocation is initiated by LFN,
the C-terminal extension with PNAs can translocate through the 12 A pore28 . In addition, this assay
allowed us to quantify the amount of material translocated. Contrary to previous delivery
techniques where most of delivered material is trapped in the endosome , we found most of the
internalized LFN-PNA is in the cytosol. These studies suggest that the LFN/PA system is highly
efficient with approximate cytosolic delivery as high as around 100 nM.
The efficiency and versatility of the LFN/PA platform allowed us to deliver an anti-sense
PNA that suppresses the CYCLOPS gene, SF3Bl, to specifically target SF3BlOss cancer cells in
a receptor-specific manner. PNAs and the LFN/PA system are ideally suited as a generalizable non-
viral lipid-free strategy to target CYCLOPS genes for three reasons: (i) The LFN/PA system enables
superior endosomal release of PNA while showing no obvious toxicity up to the highest
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concentration we tested; (ii) While the native LFN/PA delivery system can be used to deliver PNA
cargos to most cell types due to the ubiquitous expression of the ANTXR1/2 receptors, PA can be
readily engineered to target other receptors such as ERBB2 as we demonstrated; (iii) The ability
of LFN/PA to deliver PNAs of varying length and sequence indicates they can be used to target and
credential the over 100 candidate CYCLOPS genes previously identified5'6.
SF3B1 is a promising therapeutic target in cancer beyond its role as CYCLOPS gene
dependency. SF3B1 mutations have been found in many cancer types including CLL29
myelodysplastic syndrome30 ,3 1 , breast3 2 , uveal melanoma3 3 , lung3 4 , and others35 . Recent work
suggests that at least some of these cancers have increased sensitivity to spliceosome modulators
structurally related to spliceostatin A 36, which are in clinical development37 . Furthermore MYC-
38driven cancers display sensitivity to spliceosome modulators and partial SF3B1 suppression .
These observations raise the possibility that PNA-mediated suppression of SF3BJ may have
therapeutic benefits in SF3B] mutant and MYC-driven cancers, suggesting further research into
the cancer types susceptible to SF3B 1 PNA targeting.
In summary, we have demonstrated successful cytosolic delivery of the PNA constructs
studied. We verified the targeting of a CYCLOPS gene dependency by anthrax-mediated PNA
delivery in a panel of cancer cell lines across two different tissue types. Furthermore, we showed
a re-engineered PA is able to target PNA specifically to HER2-overexpressing cancer cells. This is
the first time the LFN/PA system has been used to deliver PNAs and our results show that LFN/PA
system has the potential to become a potent and generalizable method with the potential for
engineered specificity to bring the promise of PNAs to fruition and bolster oligonucleotide-based
therapy for cancer therapeutics and beyond.
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1.4. Experimental
1.4.1. Identification of cancer gene dependencies
Cancer gene dependencies were identified from analyses using a genome-scale shRNA
viability screen from project Achilles (version 2.4.3,
https://portals.broadinstitute.org/achilles/datasets/5/download). 216 cell lines were profiled for
their sensitivity to suppression of 5711 genes and had mutation calls from hybrid capture
sequencing of commonly mutated cancer driver genes (KRAS, PIK3CA, BRAF, NRAS, CTNNB1
and EGFR). Briefly, each cell line was classified as sensitive to suppression of each gene using an
ATARiS39 gene dependency threshold of >-0.75. For each gene, we performed a two-class
comparison between cell lines with and without mutation of each of the driver genes above.
Significance was calculated using fisher's exact tests and false discovery rate adjusted p values
were calculated using the Benjamini and Hochberg method4 0 . Gene dependencies identified from
the mutation of those driver genes we then combined with list of copy number associated gene
dependencies identified in a previous analysis from our group6 .
1.4.2. Estimation of the druggability of cancer gene dependencies
Classification of candidate cancer gene dependencies in traditionally druggable protein
target families was facilitated by integrating information from The British Pharmacological
Society (BPS) and the International Union of Basic and Clinical Pharmacology (IUPHAR)
database on targets and families accessed on March 2 3 rd 2017
(http://www.guidetopharmacology.org/DATA/targets-andfamilies.csv). If a cancer gene
dependency was found as a member of the protein target it was considered a candidate druggable
target, otherwise it was categorized at "challenging to drug"
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1.4.3. Protein expression and purification
His 6-SUMO-LFN-DTA(C 1 86S)-LPSTGG-His 6 , His6-SUMO-LFN-LPSTGG-His 6 , SrtA*-
His6 , wild-type protective antigen (PA), and PA[F427H] were expressed in E. coli BL21 (DE3)
cells at New England Regional Center of Excellence/Biodefense and Emerging Infectious Diseases
(NERCE). The cells were resuspended in 50 mM Tris-HCl, 150 mM NaCl, pH 7.5 buffer
containing Roche protease inhibitor cocktail and lysed by sonication. The supernatant was
subsequently loaded on the HisTrap FF crude Ni-NTA column (GE Healthcare, UK) and eluted
with 500 mM imidazole. The protein was then changed into 20 mM Tris-HCl, 150 nM NaCl, pH
8.5 buffer using a HiPrep 26/10 Desalting column (GE Healthcare). WT PA and PA[F427H] were
purified from the periplasm of E. coli BL21 (DE3) cells.
1.4.4. Synthesis of peptide nucleic acids (PNAs)
Peptide nucleic acids (PNAs) were synthesized on 0.05 mmol scale aminomethyl resin with
a Rink amide linker using Fmoc synthesis. All PNAs have 5 glycines at their N-terminus for the
purpose of sortase-mediated conjugation and 2 lysines after the glycines to increase their solubility.
After synthesis, PNAs were cleaved from resin with TFA/m-cresol (4:1) for 2 hours and dried
under N 2(g). The dried PNAs were then triturated three times with cold ether, dissolved in 0.1 %
TFA in Acetonitrile (B)/0. 1 % TFA in H20 (A), and lyophilized.
1.4.5. Peptide and PNA purification
The crude peptides and PNAs were dissolved in 99:1 A:B and purified by semi-preparative
RP-HPLC with Agilent Zorbax 300SB C 18 column (9.4 x 250 mm, 5 um) at a flow rate of 4 mL/min
using the gradient of 1-31% B over 100 min. Multiple rounds of purifications might apply if
deemed necessary. HPLC fractions were subsequently analyzed by either MALDI or LC-MS. The
final yields of the PNAs ranged from 5% to 10%.
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1.4.6. Sortase-mediated ligation
The PNAs were conjugated to LFN-DTA-LPSTGG-H 6 and LFN-LPSTGG-H 6 by 10 uM
SrtA* in sortagging buffer (10 mM CaCl2, 50 mM Tris-HCl, 150 mM NaCl, pH 7.5) for 30 minutes
at room temperature. For each reaction, 100 uM of LFN-DTA-LPSTGG-H 6 or LFN-LPSTGG-H6
and 500 ptM of G5-PNA were used. Simultaneously, the reaction mixture was incubated with Ni-
NTA beads to get rid of all the starting materials as well as H6-SrtA*. The supernatant was then
subjected to 4 rounds of 20 mM Tris-HCl, 150 mM NaCl, pH7.5 buffer exchange to remove the
excess G5-PNA.
1.4.7. Analytical liquid chromatography-mass spectrometry (LC-MS)
All LC-MS' were performed on an Agilent 6520 Accurate-Mass quadrupole time-of-flight
(Q-TOF) liquid chromatography-mass spectrometry system. We used Agilent Zorbax 300SB C3
column (2.1 x 150 mm, 5 um) with 0.1% formic acid in H2 0 at solvent A' and 0.1% formic acid in
Acetonitrile as solvent B'. A gradient of 5-65% B' over 15 min or 1-61% over 12 min was used
depending on the solubility of the construct.
1.4.8. Protein synthesis inhibition assay
The CHO-K 1 cells were maintained in F- 12K media supplemented with 10% (v/v) fetal
bovine serum at 37 'C and 5% CO 2. The cells were plated at 30K cells per well in a 96-well plate
one day before the assay. On the day of experiment, the cells were treated with indicated
concentrations of LDPs and 20 nM of PA for 30 minutes at 37 'C. They were then washed with
PBS and incubated with medium supplemented with 1 ptCi/mL 3H-leucine (Perkin Elmer, MA) for
1 hour at 37 'C. The incorporation of 3H-Leu into cellular proteins was measured to determine the
inhibition of protein synthesis by scintillation counter. All counts were normalized to cells treated
with only PA and all experiments were done in triplicate.
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1.4.9. Cytosolic protein extraction and western blot
CHO-Ki or HEK-293T cells were treated with 250 nM of LDPs or LPs and 40 nM of PA
or PA[F427H] for 12 hours at 37 'C. The cells were then trypsinized and washed with PBS. For
cytosolic extraction, ~1 million cells were resuspended in 50 - 100 ug/mL digitonin in 75 mM
NaCL, 1 mM NaH 2PO 4, 8 mM Na2HPO4, 250 mM sucrose supplemented with Roche protease
inhibitor cocktail on ice for 10 minutes and spun down at 13,000 rpm for 5 minutes at 4 'C. For
total cell lysis, lysis buffer (pH 7.5) with 25 mM Tris, 150 mM NaCl, 1% v/v NP-40 supplemented
with Roche protease inhibitor cocktail was used. Cells were lysed on ice for 30 minutes and spun
down for 10 minutes at 4 'C. Subsequently, the supernatants from both methods were run on an
SDS-PAGE gel and then transferred onto a nitrocellulose membrane soaked in transfer buffer (48
mM Tris, 39 mM glycine, 0.0375% SDS, 20% methanol) using a TE 70 Semi-Dry Transfer Unit
(GE). After the transfer is finished, the membrane was blocked with LI-COR blocking buffer at
RT for 2 hours before it was blotted against anti-LF or anti-DTA or anti-ERK1/2 and anti-Rab5 in
TBST overnight at 4 'C. The membrane was then washed and incubated with appropriate
secondary antibodies for 1 h at RT and imaged by LI-COR Odyssey infrared imaging system. The
signal intensity of each band was quantified by drawing a rectangle around it and measuring the
average signal within the rectangle using the analysis tool in Image Studio (LI-COR Biosciences).
1.4.10. Generation of isogenic SF3B1'"s cells by CRISPR Cas9
The diploid breast cancer cell line, Cal51, was used to create daughter cell lines that
differed only in SF3B] copy number. We designed gRNAs that target intergenic loci upstream and
downstream of the SF3B] locus to delete the entire gene. The 5' gRNA targeted one allele of a
heterozygous SNP (rs3 8493 62) to bias towards heterozygous SF3B] deletion because homozygous
SF3B 1 deletion is lethal. Oligonucleotides with Bbsl overhangs were annealed and cloned into
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pX458 that also encodes Cas9 and GFP (Addgene plasmid #48138). For the 5' guide targeting
rs3849362, 5' CACCGCGCATTATAGATTATGGCCC (forward) and 5'
AAACGGGCCATAATCTATAATGCGC (reverse). For the 3' targeting guide:
5'CACCGCGGAGTTTCATCCGTTACAC (forward),
AAACGTGTAACGGATGAAACTCCGC (reverse). pX458 plasmids with either the 5' or 3'
targeting guides were co-transfected into cells and GFP+ single cells were plated at 1 cell per well
by FACS.
1.4.11. PNA and siRNA delivery for cell viability assays using Cell Titer Glo
Estimation of cell viability was performed using ATP luminescence. Briefly, 1000 cells per
well were plated in 96 well plates, allowed to recover for 4-16 hours, and treated with the indicated
LFN/PA system components. Cell viability was assessed 7 days after PNA treatment. For siRNA
transfection, the same plating conditions were used, except a pool of 4 SF3B 1 siRNAs were
transfected in 6 well plated 24 hours prior to plating using Oligofectamine. The sequences for the
siRNAs were first reported in (Massiello et al., 2006)41 and are as follows:
siSF3B1 #1 (sense) 5'-GGA AUU AGA UGC UAU GUU CUU, (antisense) 5'-GAA CAU AGC
AUC UAA UUC CUU.
siSF3B1 #2 (sense) 5'-GCA AAC GAG UCA AAC CAU AUU, (antisense) 5'-UAU GGU UUG
ACU CGU UUG CUU
siSF3B1 #3 (sense) 5'-GAA CCG CUA UUG AUU GAU GUU, (antisense) 5'-CAU CAA UCA
AUA GCG GUU CUU
siSF3B1 #4 (sense) 5'-GUA GAA UGU UGC AAU AUU GUU, (antisense) 5'-CAA UAU UGC
AAC AUU CUA CUU
siLacZ control (sense) 5'-UGU UCG CAU UAU CCG AAC CUU, (antisense) 5'-GGU UCG
GAU AAU GCG AAC AUU
1.4.12. Determination of cellular sensitivity to chemical modulation of the spliceosome
Cells were plated at 10,000 cells per well in 96 well plates. 24 hours after seeding, cells
were treated with the indicated concentrations of splicing modulator. Relative cell viability was
expressed as the percent change in Cell Titer-Glo luminescence normalized to vehicle (DMSO)
treated cells. Spliceostatin A was a gift of Dr. Minoru Yoshida24
1.4.13. Splicing luciferase reporter assays
Polyclonal, stable CRISPR eutral and CRISPRcoPY'~oss cells were generated by transfection
and hygromycin selection. Cells expressed either CMV-LUC2CP/intron/ARE (Luc-I in this
manuscript, Addgene plasmid # 62858) or CMV-LUC2CP/ARE (Luc-ORF in this manuscript,
Addgene plasmid # 62857) which were gifts from Gideon Dreyfuss42 . To calculate the fold change
in splicing activity, the ratio of Luc-I:Luc-ORF was calculated after normalizing to sense SF3B 1
PNA treated cells.
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1.5. Significance
Targeted therapeutics have provided notable successes for the treatment of cancer, however there
remains a scarcity of effective therapies. In order to augment the number of potential therapeutic
strategies, a comprehensive catalog of candidate cancer therapeutic targets is needed. Furthermore,
versatile and effective delivery methods for these therapeutics presents a major barrier to success.
To address these challenges, we analyzed genome-wide shRNA viability screens and identified
486 genes that are required for cancer cell survival that are associated with a cancer-specific
somatic genetic alteration. Strikingly, we estimate that only 13% of these cancer gene
dependencies are members of "druggable" protein classes. However, antisense gene suppression,
such as through peptide-nucleic acid conjugates (PNAs), represents a generalizable approach to
target cancer gene dependencies. Here we developed a non-viral, lipid-free delivery system using
engineered components of anthrax toxin. We demonstrate efficient delivery of anti-sense PNAs
across cell membranes and into the cytosol and target gene suppression. In proof of concept
studies, we demonstrate that anthrax delivered PNAs can target cancer specific gene dependencies
on the essential spliceosome component SF3BJ. This dependency on SF3B 1 is one of over 120
examples of CYCLOPS (Copy number alterations Yielding Cancer Liabilities Owing to Partial
LosS) dependencies, indicating a vast set of dependencies that may be exploited by our PNA
delivery system.
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Figure 1.7.1. LC-MS traces of the PNA constructs used in this study. All the PNAs have N-
terminal G5 tags. All LC-MS' were performed on an Agilent 6520 Accurate-Mass quadrupole
time-of-flight (Q-TOF) liquid chromatography-mass spectrometry system. We used Agilent
Zorbax 300SB C3 column (2.1 x 150 mm, 5 um) with 0.1% formic acid in H20 at solvent A' and
0.1% formic acid in Acetonitrile as solvent B'. A gradient of 5-65% B' over 15 min or 1-61% over
12 min was used depending on the solubility of the construct.
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Figure 1.7.2. LC-MS traces of LDPs and LPs used in this study. The LC-MS' were performed
as described in Supplementary Figure 1.
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Figure 1.7.3. Coomassie stained SDS-PAGE gel of LFN-DTA-PNA9 (LDP9) and LFN-PNA9
(LP9).
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Figure 1.7.4. Western blot showing the translocation of LP9*, a scrambled version of LP9.
HEK-293T cells were treated with 250 nM of LP9 and 40 nM of PA or PA[F427H] for 12 hours.
The cells were subsequently subjected to digitonin extraction or total lysis (~A million cells per
lane). Purified LP was also run on the gel for the purpose of quantification.
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Figure 1.7.5. Linear relationship between band intensity and the amount of protein loaded.
1.0-10.0 ng of pure LP9 was loaded on the gel and the signal intensity of each band was analyzed
by Image Studio (LI-COR Biosciences).
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Figure 1.7.6. Western blot showing the translocation of LDP6-9. Cells were treated with 100
nM of LDP and 20 nM of PA or PA[F427H] for 12 hours. The cells were subsequently subjected
to digitonin extraction. Purified LDP was also run on the gel as a loading control. a) Translocation
of LDP6-8 in HEK-293T cells. b) Translocation of LDP7 and LDP8 in CHO-Ki cells. c) Translo-
cation of LDP9 in HEK-293T cells. BA stands for Bafilomycin Al, which inhibits the acidification
of the endosome. It was used as a negative control to validate the translocation pathway.
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Figure 1.7.7. Dose response curve for CRISPR"neural (black) and CRISPR"Py"'s cells (red)
upon treatment with the splicing modulator, Spliceostatin A. Relative viability was quantified
by Cell titer glo and normalized to DMSO vehicle control. Representative experiment performed
in triplicate.
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Figure 1.7.8. SF3B1 immunoblot in CRISPRne"t-al and CRISPR*"PY-'o" cells. Isogeneic Cal51
cells treated with transient transfection of Cas9 sgRNAs upstream and downstream of the SF3B 1
locus and screened for single copy SF3Bl deletion. Cells were then lysed and evaluated for the
effects of partial SF3B 1 copy loss on protein levels.
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Figure 1.7.9. Sensitivity of CRISPR"eutraI and CRISPR'"ss Cal5l cells in the presence of dif-
ferent concentrations of siRNA that suppresses SF3B1. a) SF3B1 mRNA expression level upon
siRNA transfection by quantitative PCR with the indicated concentrations of siRNA. Relative
SF3B1 expression was normalized to siLacZ transfected cells in CRISPRneutraI cells (black) and
CRISPRoss cells (red). b) Dose response curve for relative cell viability of CRISPR neutral (black)
and CRISPRcoPy-Oss (red) cells upon siRNA-mediated SF3B 1 suppression. Cell viability calculated
as the fold change in Cell Titer-Glo luminescence relative to siLacZ control. Representative ex-
periment performed in triplicate. For all panels, Error bars represent +- SD.
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Figure 1.7.10. The in vitro binding of PNA10 to its DNA substrate measured by electropho-
retic mobility shift assay. 1 uM of a DNA-Cy3 probe that hybridizes with the anti-sense SF3B 1
PNA was incubated with indicated concentration of PNA1O (anti-sense SF3B1 PNA) or LP1O
(anti-sense SF3B1 PNA conjugated to LFN) for 2 hours at room temperature. The mixture was
then subjected to gel electrophoresis and imaged with a Typhoon FLA 7000 scanner (GE). a) The
binding to the DNA substrate by LFN only, PNA 10, or a negative control PNA* measured by the
band shift. b) The binding to the DNA substrate by LP10 or the negative control LFN-PNA* (LP*).
The DNA/PNA complex band observed resulted from some residual PNA1O after the conjugation
of LFN and PNA 10.
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Figure 1.7.11. Immunoblot after treatment with LFN sense or anti-sense SF3B1 PNAs in
CRISPR*SS cells. Western probed with SF3B 1 and anti-LF antibodies with 8, 40, or 250 nM LFN-
conjugated antisense SF3B 1 PNA in the presence of 50 nM PA. 250 nM LFN-conjugated SF3B 1
sense PNA was used as a control. Lysates were collected four days after LFN/PA PNA delivery.
Actin was used as a loading control.
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1.7.1. Supplementary notes:
Definition of terms
Gene dependency - A gene, that when suppressed by RNAi, results in decreased cellular fitness.
Somatic genetic alteration - A genetic change that deviates from the normal germline DNA se-
quence, including mutations or copy number changes. These alterations accumatuate in cells and
contribute to cellular transformation.
Cancer gene dependency - A gene dependency that is associated with a cancer specific somatic
genetic alteration. The association with a genetic alteration suggests the gene is only required for
cancer cell, but not normal cell survivial because the normal cells lack the associated genetic event
Driver gene - A gene, that when altered by a somatic genetic alteration (i.e. mutation or copy
number change), contributes to cellular transformation and cancer.
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1.7.2. Inhibition of telomerase by LFN/PA delivered anti-sense PNA
In addition to targeting SF3B 1, we investigated the delivery of anti-sense PNA to inhibit
telomerase. Telomerase catalyzes the addition of telomeric repeats onto the 3' end of a specific
sequence of DNA using its RNA component as the template43'44 and it has been shown to play a
key role in cancer proliferation4 5. Telomeric Repeat Amplification Protocol (TRAP) is a PCR-
based assay that detects the activity of telomerase by amplifying and measuring telomeric repeats,
which is the product of telomerase 45 (Figure 1.7.12). The TRAP assays were performed using the
TRAPeze kit (Millipore).
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Figure 1.7.12. A schematic diagram showing how Telomeric Repeat Amplification Protocol
(TRAP) assays work.
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I
LP9 is one of the model PNAs we used to characterize PNA delivery by LFN/PA and it is
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also a reported inhibitor of telomerase . We first tested the inhibition of telomerase by LP9 using
cell lysate. Both HEK-293T (human embryonic kidney) and A-431 epidermoid carcinoma cells
were used for the assays and both have been shown to be dependent on telomerase function. One
million cells were lysed using CHAPS buffer and a subset (600 cells) were analyzed for (4 gl of
150 cell equivalents/ptl) telomerase activity. The cellular extracts were preincubated at 25 'C for
30 minutes with LP9 or LP 10 at the indicated concentrations. Following preincubation, 2 gi of the
cellular extract containing LP9 or LP10 was added to a PCR tube with a reaction mixture (Tris
buffer, TS primer, CX primer, IS primer, dNTP, and Taq polymerase) and incubated for 30 min at
30 'C to allow the elongation of the TS primer. Then the amplification step was performed through
30 cycles of PCR (30 seconds at 95 'C, 30 seconds at 50 'C, 45 seconds at 72 'C) and the resulted
products were loaded onto a 10% nondenaturing polyacrylamide gel. Gels were stained with eth-
idium bromide, imaged by UV and processed with ImageStudio. For each condition, the total flu-
orescence intensity was summed and normalized to the internal standard for the quantification.
LP9 was shown to effectively inhibit telomerase activity from both HEK-293T and A-431 lysate
at concentrations above 10 nM (Figure 1.7.13). Unlike LP9, LPlO, a scrambled version of LP9,
showed no inhibition of telomerase activity even at 1 pM, indicating that complementary binding
between the PNA and the template region of human telomerase RNA (hTR) is necessary for this
action. The absence of any product bands in the no-lysate control confirmed the bands were due
to the telomerase activity instead of any nonspecific Taq activity.
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Figure 1.7.13. TRAP assay showing inhibition of telomerase activity by LP9 in both HEK-
293T and A431 cells. LP10 was used to confirm the complementation is required for the inhibi-
tion. The 36-bp internal standard (IS) strand is noted. The lane denoted "No lysate" represents a
negative control to which no cell lysate was added.
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After confirming the inhibition of telomerase by LP9 with cell extracts, we proceeded to
inhibit telomerase inside cancer cells by translocating LP9 with PA. A-431 cells were incubated
with 250 nM of LP9 in the presence of 40 nM of PA for 60 hours prior to harvesting. The cells
were subsequently subjected to TRAP assays as described above. 35% inhibition of telomerase
activity was observed for the LP9 + PA treated sample, as compared to the negative controls (PNA9
only, PNA9 +PA, LP10 +PA, LFN + PA, LP9 + PA[F427H], and LP9 only) (Figures 1.7.14-15). A
previous report found that 8 lysine residues covalently attached to the C-terminus of a PNA de-
signed to cause exon skipping was delivered into cells by PA. However, we failed to observe
inhibition of telomerase activity with PNA9-K8 event in the presence of PA. Moreover, a cell-
penetrating TAT peptide was also conjugated to PNA9 and it too failed to inhibit telomerase activ-
ity in the cell. The fact that no inhibition was observed when either PA or LFN was absent indicates
their indispensable roles during translocation. Finally, we used LP 10 with a mismatched PNA se-
quence as an additional negative control to confirm that inhibition occurred through the hybridi-
zation between LP9 and the template region of hTR.
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Figure 1.7.14. Telomeric repeat amplification protocol (TRAP) assays. A431 cells were treated
with 250 nM of indicated compounds for all experiments for 60 hours. After treatment, cells were
trypsinized, washed, and assayed for telomerase activity. All experiments were carried out three
times and for each trial TRAP products were run on a 10% non-denaturing acrylamide gel (a rep-
resentative gel from one of the trials is shown).
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Figure 1.7.15. Telomeric repeat amplification protocol (TRAP) assays. A431 cells were treated
with 250 nM of indicated compounds for all experiments in the presence or absence of 40 nM PA
for 60 hours. After treatment, cells were trypsinized, washed, and assayed for telomerase activity.
All experiments were carried out three times and for each trial TRAP products were run on a 10%
non-denaturing acrylamide gel (Figure S8). Telomerase activity was quantified by UV fluores-
cence from ethidium bromide and processed with ImageStudio. For each condition, the total fluo-
rescence intensity was summed and normalized to the internal standard with in the same well for
the quantification. All the data points from each trial were normalized to cell only. P values were
calculated using the Student's t-Test.
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Chapter 2: Antibody-directed Cytosolic Delivery of Proteins enabled
by Orthogonal Targeting
70
2.1. Introduction
Proteins such as hormones, cytokines and antibodies have emerged as one of the most im-
portant classes of drugs"2 . However, most proteins cannot be used against intracellular targets due
to their inability to reach the cytosol13 4. Although gene delivery has been extensively used to in-
troduce exogenous proteins into cells, it risks permanent disruption of the endogenous genome5.
Several approaches including peptides6, polymers7, and nanoparticles '9 have been developed for
direct protein delivery but most of them either lack specificity or have limited endosomal release,
two key features of an ideal protein delivery strategy.
Monoclonal antibodies (mAbs) are ideal molecules for targeting. They have been exploited
in almost every branch of biomedical research and are widely used in humans for the treatments
of immune-related diseases and cancer as one of the most successful and important therapeutic
strategies1 0-12. Today more than 70 mAb drugs have been approved and more than 550 antibodies
are in clinical development'3 . Among them, the predominant form is immunoglobulin G (IgG)".
IgG is composed of two distinct functional units: the antigen binding fragment (Fab), which con-
fers antigen specificity, and the constant fragment (Fc), which interacts with the immune cells and
extends the antibody half-life in vivo' . Due to their great versatility and clinical relevance, there
has been a considerable amount of interest in using IgG molecules as drug carriers to target specific
type of cells' 5 . Antibody drug conjugates (ADCs) and immunotoxins are two examples of using
mAbs or mAb fragments to deliver cytotoxic moieties to cancer cells,6 ' 17. During its general mech-
anism of action, the ADC is endocytosed via the antibody-receptor interaction into the endo-
some/lysosome, where the small molecule drug is released from the antibody and diffuses out of
the endosome into the cytosol1'8 19. In the case of immunotoxin, after its release from the antibody,
the protein toxin self-transports into the cytosol due to its unique natural toxin-derived property20
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However, for the majority of proteins, the cytosolic delivery using mAbs has remained elusive due
to their inability to escape the endosome.
Fortunately, nature has evolved several types of translocation systems for delivery of pro-
teins into host cells. Among them, anthrax lethal toxin is a good example of using a translocase
to deliver protein toxins from the endosome to the cytosol. It is composed of three proteins, the
translocase protective antigen (PA), and the effector proteins lethal factor (LF)22 and edema factors
(EF)2 3 . During its mechanism of action, PA83 its receptors on host cell surface and then is proteo-
24 claaelytically cleaved into PA63 by furin-family protease2. Upon cleavage, PA6 3 oligomerizes into a
heptameric2 or octameric26 pre-pore and three or four LF molecules bind to the pre-pore through
their N-terminal domain LFN with 1-2 nM affinity 27,28. The entire complex is subsequently endo-
cytosed and the acidic pH in the endosome causes conformational change of the pre-pore to form
a trans-membrane pore, which enables the translocation of LF from endosome into cytosol 2 9- 3 1.
By hijacking this cytosolic delivery machinery, researchers have demonstrated the cellular
delivery of a wide variety of molecules including proteins, peptides, and small molecules. These
studies have shown LFN/PA system can efficiently deliver enzymes or enzymatic domains such as
beta-lactamase32 , Diphtheria toxin A (DTA)33 , Pseudomonas exotoxin A34, Ras protease RRSP35,
etc. Moreover, antibody mimics3 6 as well as non-natural entities such as mirror image polypeptides
and proteins 37 have also been translocated into cells using the LFN/PA system. In addition to dif-
ferent cargos, retargeted PAs have also been investigated 38' 39. Notably, the Leppla group has re-
ported PA mutants with altered protease sites that can only be activated by matrix metalloprotein-
ase (MMP) 40 or urokinase-type plasminogen activator (uPA)41, both of which are proteases over-
expressed on tumor cells. In this study, we report a novel generalizable antibody-directed protein
delivery system by chemically conjugating the protein translocase PA to IgG molecules using the
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strategy diagrammed in Fig. 1a. Taking advantage of the modularly designed system, we investi-
gated the delivery of different cargo proteins by different antibodies. Based on the unique property
of PA, we created IgG PA conjugates that are able to orthogonally target specific antigen and
protease on cell surface simultaneously and demonstrated the efficient delivery of DTA in different
cancer models both in vitro and in vivo.
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2.2. Results
2.2.1. Modular design of antibody protective antigen conjugate
When we first sought out to design the antibody PA conjugate, we rationalized that an ideal
such system would meet four criteria: 1. Both the antibody and PA should be able to carry out their
functions as antigen binder and protein translocase in the conjugate (Figure 2.2.1 a). 2. The conju-
gate should be relatively stable in a biological environment. 3. The conjugate should be a homo-
geneous pure substance. 4. The conjugate should be easy to prepare.
Recombinant expression is a common strategy used to create fusion proteins. Two con-
ceivable ways could be explored for this purpose, with PA expressed either on the N-terminus or
C-terminus of the heavy chain/light chain (Figure 2.2.1 b). However, significant challenges exist
with both approaches. If PA is on the N-terminus of the heavy chain or light chain, there is a high
probability that the binding of the antibody will be affected due to the proximity of PA to the
antigen binding region. If PA is on the C-terminus, PA6 3 will be cleaved off antibody upon binding
to the cell surface and unable to form the pre-pore. This is because PA is only activated after its
N-terminal PA20 is proteolytically cleaved by furin-family protease to give PA6 3 , leading to for-
mation of pre-pore. Due to these pitfalls, we concluded the recombinant strategy is not suitable in
this particular case because it cannot satisfy the first and the most important criterion listed above,
to retain the functionalities of both proteins.
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bAb binding affected
Ab cleaved with PA
Chemical ligation
Figure 2.2.1. Modular design of immunoglobulin (IgG) protective antigen (PA) conjugate. a)
The proposed mechanism of antibody-mediated delivery by the IgG-mPA system. b) Different
possible strategies of conjugating mPA to IgG. Recombinant expression was ruled out due the
potential impact on the functionality of IgG or PA.
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Chemical conjugation is an alternative to recombinant expression and it gives us more
freedom to design the conjugate. In order to preserve the functions of both proteins, we conjugated
the C-terminus of the heavy chain, away from the antigen binding site, to the middle of the PA6 3
domain of PA using sortase-mediated ligation. We first created a PA variant on which a polygly-
cine linker can be installed for conjugation. A single cysteine mutation was introduced at the pre-
viously reported lysine 563 position42 of PA(N682A, D683A), a known PA mutant with ablated
native receptor-binding ability while retaining its translocase activity43. We were able to express
and purify the resulted mutant protein mPAC from Escherichia coli B121 (DE3) in high yield (Fig-
ure 2.6.1). A short D-peptide linker with an N-terminal tri-glycine was crosslinked to the cysteine
of mPAC through bromoacetamide (Figure 2.2.2a). The resulted G3-mPA was subsequently li-
gated by a triple mutant sortase (SrtA*) 44 onto an IgG molecule with inserted C-terminal LPSTGG
tag at its heavy chains. This reaction gave a product mixture of both mono- and dual-mPA tagged
IgGs, which was then purified to homogeneous IgG-mPA by size exclusion and anion exchange
chromatography with a final yield of greater than 50% (Figure 2.2.2b).
This conjugation strategy was designed to fulfill all four criteria we originally sought for
the system. The attachment sites on both mPA and IgG were carefully chosen to avoid interference
with their functions as antigen binder and translocase. The C-termini of the heavy chains were
used for conjugation to minimize the potential impact of mPA on the IgG molecule and the cyste-
ine was introduced in the PA63 domain so that IgG would remain attached after protease-mediated
activation of mPA. We performed an in-vitro SDS-resistant pore formation assay to confirm the
activity of mPA after attachment to IgG (Figure 2.6.7). Additionally, unlike ADCs or immunotox-
ins, of which the payloads need to be released from the antibody at the target site, IgG-mPA needs
to remain intact during its mechanism of action and the cargo protein comes as a separate entity.
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Toward this end, the short bromoacetamide D-peptide linker between IgG and mPA was designed
to minimize potential cleavage in a biological environment. Indeed, IgG-mPA prepared with this
linker showed no appreciable degradation in 10% serum up to 7 days whereas the maleimide linked
conjugate started showing cleavage after 8 hours under the same condition, consistent with previ-
ous reports'"' (Figure 2.6.8). A longer poly GGS maleimide linker was also tested and exhibited
similar activity to the short maleimide linker, indicating the length of the linker does not play a
major role (Figure 2.6.9). All IgG-mPA conjugates used in this chapter were thus prepared with
the bromoacetamide D linker unless stated otherwise. Moreover, in order to obtain homogeneous
IgG-mPA, we took advantage of the pI difference between IgG-mPA and IgG-(mPA) 2 and suc-
cessfully separated them by anion exchange. IgG-mPA was chosen to limit the possible effect on
the properties of the IgG, although IgG-(mPA) 2 is also active (Figure 2.6.10). We also found that
IgG-(mPA)n prepared by non-specific conjugation using a NHS-Maleimide linker was capable of
delivery despite its reduced potency (Figures 2.6.11-12). Last but not least, the entire process of
conjugation and purification takes less than half a day and can be scaled up easily, fulfilling the
fourth requirement.
Since the cleavage site of mPA can be engineered to target different proteases, mPA vari-
ants with different protease specificities were also generated for IgG conjugation. Unlike the re-
combinant method in which each protein needs to be prepared individually, our conjugation strat-
egy enables rapid combinations of different antibodies and mPA variants in a modular fashion
(Figure 2.2.2c). The resulted IgG-mPA variant would require the simultaneous presence of the
IgG-specific antigen and the PA-specific protease for activation as demonstrated later in the results
(Figure 2.2.2d).
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Figure 2.2.2. Preparation of IgG-mPA conjugate using sortase-mediated ligation. a)
mPA(K563C) was put on a polyglycine linker by either maleimide or bromoacetamide before sort-
agging onto IgG with LPSTGG tags. b) The resulted product mixture of IgG-mPA and IgG-(mPA) 2
was purified to homogeneous IgG-mPA by standard size exclusion and anion exchange chroma-
tography. The IgG in this experiment is Trastuzumab. The preparation of other IgG-mPA variants
are described in the supplementary information. c) Free combinations of different antibodies and
different mPA variants enable orthogonally targeted delivery of different protein cargos. d) Sche-
matic showing IgG-mPA variant delivers a protein cargo to specific cell type by dual targeting of
particular antigen and protease.
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2.2.2. Antibody-mediated delivery of different protein cargos in specific cell types
Epidermal growth factor receptor (EGFR) and HER2 are among the most studied cell sur-
face receptor tyrosine kinases. They are implicated in tumor development and are overexpressed
in a wide variety of human cancers including breast, ovarian, lung, colon, etc4-1. The high interest
in these receptors as anticancer targets has led to the development of various therapeutics from
small molecule inhibitors to large antibodies. Trastuzumab (Tmab) and cetuximab (Cmab) are two
humanized recombinant monoclonal antibodies that bind to HER2 and EGFR respectively'.
They both have been approved by FDA years ago and are therefore suitable for our study.
We first investigated the ability of Tmab-mPA, prepared as described above, to deliver
LFN-DTA into HER2 positive cells. LFN-DTA (LD) is a fusion protein between LFN, the PA pre-
pore binding domain and DTA, the catalytic domain of diphtheria toxin. The DTA moiety inhibits
protein synthesis and causes cell death by ribosylating the eukaryotic elongation factor 2 within
the cytosol5 4 . We found that 10 nM LD in the presence of Tmab-mPA effectively reduced the
viability of HER2-overexpressing BT474 cells5 5, indicating potent cytosolic delivery of DTA,
whereas LD in the presence of unconjugated Tmab/mPA only exhibited similar antiproliferative
effect to Tmab-mPA or Tmab alone (Figure 2.2.3a). We then examined whether the translocase
function of PA is required for the DTA delivery by using mPA(F427A), a mutant PA that is inca-
pable of translocation but still binds LFN56 . As expected, LD with Tmab-mPA(F427A) failed to
show any enhanced activity. To be thorough, we conjugated LD directly to Tmab (Figure 2.6.13).
The conjugate Tmab-LD also did not show any increased killing, confirming mere endocytosis of
LD is not enough to trigger DTA activity.
We next wanted to see if such delivery strategy can be expanded to another antibody. EGFR
overexpressing A431 cells were treated with Cmab-mPA in the presence of LD under the same
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conditions. Just like in the case of Tmab-mPA, only Cmab-mPA combined with LD showed sig-
nificant antiproliferative effect in A431 cells, whereas no other treatment showed any difference
from Cmab alone, verifying both Cmab and functional PA are both required for the cytosolic de-
livery of DTA (Figure 2.2.3b). These results provided strong evidence that this IgG-mPA cytosolic
delivery strategy can be applied to different antibodies targeting different antigens.
We then investigated the specificity of this delivery method in different cell lines. When
we treated BT549, a triple negative breast cancer (TNBC) cell line lacking HER257 , with Tmab-
mPA and LD under the same conditions as BT474, no significant reduced viability was observed
up to the highest concentration tested (Figure 2.2.3c). Likewise, when we challenged EGFR neg-
ative Jurkat cells with Cmab-mPA and LD, the cells showed very little change of viability (Figure
2.2.3d). In contrast, significant toxicities were observed when we treated both cell lines with
wildtype PA and LD (Figure 2.6.14). In addition, to further verify the specificities of IgG-mPA
conjugates, same cell lines were treated with Tmab-mPA or Cmab-mPA in the presence of LD.
We observed major toxicity difference between the two conjugates in good accordance with the
relative HER2 and EGFR expression level (Figure 2.6.15). Taken together, these data suggest IgG
and mPA can retain their separate functions in the conjugate and the delivery of the protein cargo
depends on both of them.
After verifying the delivery of DTA by IgG-mPA, we further explored whether such a
system can be used to deliver other protein cargos. Edema factor (EF), one of the native effector
proteins of anthrax toxin, is a calmodulin and Ca 2 dependent adenylate cyclase, which increases
intracellular concentration of cyclic AMP (cAMP) 23 . cAMP has been found to be involved in a
variety of biological processes including the immune system5 8 . As a result, several drugs have
been or are being developed to modulate cAMP level to attenuate autoimmune and inflammatory
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diseases59 . Here we demonstrate the ability to increase intracellular cAMP concentration through
antibody-directed delivery of EF. EGFR-expressing TNBC MDA-MB-231 cells5 5 were incubated
with 20 nM of EF in the presence of Cmab-mPA or other controls for 2 hours and the cAMP levels
were subsequently measured by a commercial ELISA-based competition assay. We observed sig-
nificant elevation of cAMP level only when Cmab-mPA was used as the delivery vehicle. Trans-
location-disabled Cmab-mPA(F427A) failed to enhance cAMP concentration, suggesting entrap-
ment of EF in the endosome. Unconjugated Cmab/mPA also showed similar level of cAMP to the
untreated background, indicating conjugation is required for the activity of IgG-mPA (Figure
2.3.3e). Additionally, Tmab-mPA with EF failed to increase the cAMP level, confirming again the
delivery is antibody-dependent. When we replaced the cargo protein with LD, little change of
cAMP level was detected, demonstrating the effect is cargo specific.
We further expanded the protein cargo library to a third protein. Ras is an oncoprotein that
plays a critical role in cancer development and Ras/Rap 1-specific endopeptidase (RRSP) is a re-
cently characterized Ras protease that rapidly cleaves Ras once delivered into cells by wildtype
PA3 5 . MDA-MB-231 cells were treated with LFN-RRSP (LR) in the presence of Cmab-mPA and
other controls for 24 hours. The cells were subsequently lysed and analyzed by Western blots. As
shown in Figure 2.2.3f, Ras exhibited dose-dependent degradation as a result of RRSP induced
cleavage. ERK is a downstream target protein activated by Ras and a key player in cell growth
regulation. While the total amount of ERK remained unchanged across different conditions, phos-
pho-ERK (pERK) showed dose-dependent suppression similar to Ras in the presence of LR and
Cmab-mPA, indicating ERK1/2 dephosphorylation caused by RRSP. On the contrary, just like in
the previous experiments, Cmab-mPA(F427A), unconjugated Cmab/mPA and Tmab-mPA did not
show any obvious activity compared to the background.
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Figure 2.2.3. IgG-mPA delivers different protein cargos to different cell types in a receptor-
specific manner. a) HER2 expressing BT474 cells were treated with ten-fold serial dilutions of
Tmab or Tmab conjugates with or without 10 nM LD in medium containing 10% FBS for 72 hours.
mPAA stands for mPA(F427A), a translocation-deficient mutant of mPA. The cell viabilities were
measured by CeilTitor-Glo assay and normalized to untreated cells. b) EGFR expressing A431
cells were treated with Cmab or Cmab conjugates the same way as described in a. c) Viability
comparison between HER2 positive BT474 and HER2 negative BT549 cells after treatment with
Tmab-mPA and 10 nM LD. d) Viability comparison between EGFR positive A431 and EGFR
negative Jurkat cells after treatment with Cmab-mPA and 10 nM LD. e) EGFR expressing TNBC
MDA-MB-231 cells were treated with 20 nM EF or LD and different Cmab or Tmab conjugates
for 2 hours. The intracellular cAMP concentrations were measured by an ELISA-based competi-
tion assay. f) MDA-MB-231 were incubated with different concentrations of LR in the presence
of 50 nM Cmab-mPA for 24 hours. 50 nM of LR with different Cmab or Tmab conjugate controls
were also included.
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2.2.3. Overcome drug resistance in different HER2 and EGFR expressing cancer cell lines
with Trastuzumab and Cetuximab mediated delivery of diphtheria toxin A
Since the approval of Tmab (Herceptin) for the treatment of HER2-overexpressing breast
cancer, a significant number of patients with this type of breast cancer have developed resistance
to Tmab treatment60,6 1 . Similarly, EGFR inhibitors such as Gefitinib and Cmab (Erbitux) have also
62-64been found to be ineffective in EGFR-positive cancer patients2-. Such resistance is often at-
tributed to RAS mutations that lead to constitutive activation of EGFR signaling65 . In addition,
previous studies have shown cancer cells often still retain HER2 or EGFR expression when they
become refractory to HER2- or EGFR-based therapies 64,66,67 . Based on these results, we hypothe-
sized the drug resistance could be overcome by Tmab- and Cmab-directed delivery of DTA, which
induces cellular toxicity through a different mechanism.
Upon the intoxication of LD+Tmab-mPA, HER2-expressing ovarian cancer cell line
SKOV-3 displayed dose-dependent cell growth inhibition but showed little response to Tmab treat-
ment (Figure 2.2.4a). Likewise, EGFR-positive human non-small-cell lung cancer (NSCLC) cell
lines A549 and H44 1, colorectal cancer cell line HCT- 116, TNBC cell lines BT549 and MDA-
MB-231 all showed high susceptibilities to LD+Cmab-mPA and no significant response to Cmab
or Gefitinib treatment, consistent with previous studies6 8-70 (Figures 2.2.4b-f).
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Figure 2.2.4. Resistance to HER2 or EGFR based therapies can be overcome by Tmab or
Cmab delivered DTA. Different refractory cancer cell lines were treated with either IgG or IgG-
mPA/LD in medium containing 10% FBS for 72 hours. The Cmab resistant cell lines were also
treated with Gefitinib, an FDA approved EGFR inhibitor. The relative cell viabilities were meas-
ured by CellTitor Glo assay and normalized to untreated cells. a) Human ovarian cancer cell line
SKOV-3. b, c) Human non-small-cell lung cancer (NSCLC) cell lines A549 and H441. d) Human
colon cancer cell line HCT- 116. e, f) Triple negative breast cancer (TNBC) cell lines BT549 and
MDA-MB-231.
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2.2.4. Orthogonal targeting of cancer specific receptors and proteases by IgG-mPA variants
Although HER2 and EGFR are often overexpressed in cancer cells, they also play essential
roles in regular cellular functions and therefore are present in normal tissues 71 ,72 . In fact, it is rare
to find a single antigen exclusively on the cells of interest. This could be particularly problematic
when the delivered cargo is a highly toxic protein due to the possibility of off-target effect. How-
ever, the specificity of a delivery system can be significantly enhanced if it requires two entities
simultaneously at the target site for activation. During PA-mediated translocation, after binding to
its cellular receptors, PA can only oligomerize upon cleavage by furin-family proteases after the
sequence RKKR 24. Leveraging this requirement of a protease during PA activation, the Leppla
group has developed PA variants with re-engineered cleavage site susceptible to MMP or uPA40'4
both of which are over produced by tumor tissues and implicated in cancer cell growth and metas-
tasis. Here we combined these PA variants with an IgG molecule using the modular conjugation
strategy and created Cmab-mPA-MMP and Cmab-mPA-uPA, which orthogonally target EGFR
and MMP or uPA. These dual targeting IgG-mPA variants require the concurrent presence both
the antigen and a specific cell surface protease for activation (Figure 2.2.2d), providing another
degree of selectivity for the delivery system. Using these variants, we demonstrated highly specific
delivery of DTA into particular cancer cell lines.
We first verified the susceptibilities of Cmab-mPA, Cmab-mPA-MMP and Cmab-mPA-
uPA to proteases furin, MMP and uPA respectively. The conjugates were incubated individually
with furin, uPA, or MMP-9 for 3 hours at 37'C and analyzed by reducing SDS-PAGE gel, which
reduced the conjugates to mPA tagged heavy chain (HC-mPA), HC, and light chain (LC). The
cleavage of mPA was indicated by the downward shift of HC-mPA to HC-mPA63 and the appear-
ance of PA20 band (Figure 2.2.5a). As expected, each conjugate variant was only vulnerable to its
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specific protease. The band between HC-mPA 63 and HC in MMP-9 treated Cmab-MMP was pos-
sibly caused by subsequent cleavage of HC-mPA63 by MMP-9.
We then tested the hypothesis that Cmab-mPA-MMP and Cmab-mPA-uPA can target cells
with both EGFR and their corresponding proteases. LD was again used as a model protein cargo
due to its robust viability readout. TNBC cell lines BT549 and MDA-MB-23 1, which express
EGFR, MMP-9, and uPA73'74, were treated with Cmab-mPA-MMP or Cmab-mPA-uPA in the
presence or absence of LD for 72 hours. Both cell lines showed high sensitivities to the IgG-mPA
variants that is comparable to Cmab-mPA, indicating the modified cleavage site did not signifi-
cantly affect IgG-mPA activity when the targeted protease is present (Figures 2.2.5b-c). In con-
trast, H2030 cells, which are EGFR positive but lack MMP and uPA75, showed complete resistance
to LD with Cmab-mPA-MMP and Cmab-mPA-uPA but not with Cmab-mPA (Figure 2.2.5d). In
addition, more attenuated LD toxicity was observed when normal human endothelial HMEC-1
cells were treated with Cmab-mPA-MMP and Cmab-mPA-uPA when compared to Cmab-mPA,
consistent with our assumption that the dual-targeting further improves the specificity of the de-
livery system. Meanwhile, HMEC- 1 still remained highly susceptible to wild-type PA + LD, con-
firming the cell line is still sensitive to LD delivery (Figure 2.2.5e).
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Figure 2.2.5. Orthogonal targeting IgG-mPA variants require the presence of both the anti-
gen and the protease for cargo delivery and hence have less off-target effect. a) In vitro cleav-
age of Cmab-mPA, Cmab-mPA-uPA (Cmab-uPA), and Cmab-mPA-MMP (Cmab-MMP) by
furin, uPA, or MMP-9. The Cmab conjugate was incubated with the corresponding protease at
37*C for the times indicated. The samples were analyzed by SDS-PAGE and stained with coo-
massie dye. b) EGFR/uPA positive MDA-MB-231 and BT549 cells were treated with or without
10 nM LD in the presence of ten-fold serial dilutions of Cmab-mPA-uPA for 72 hours before
subjecting to CellTitor Glo assay. c) MDA-MB-231 and BT549 cells, which also express MMP,
were treated with Cmab-mPA-MMP and LD as well. d) EGFR positive and uPA/MMP negative
H2030 cells were incubated with serial dilutions of all three Cmab conjugates and 10 nM LD. e)
Cytotoxicities of LD delivered by wild-type PA or different Cmab-mPA variants were tested in
normal human microvascular endothelial cell line HMEC- 1.
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2.2.5. Protein toxin delivered by orthogonal targeting Cmab-mPA variants showed signifi-
cantly improved safety profile and pharmacokinetic properties
We next investigated whether the attenuated toxicity observed in cell culture was able to
translate into an animal model. Female nude mice were challenged intravenously with 1 mg/kg of
LD alone or in combination with increasing amounts of Cmab-mPA-uPA or Cmab-mPA-MMP.
The injected mice were closely monitored for any outward signs of toxicity for 48 h. After the
mice were sacrificed, the tissue samples from kidney and liver were also subjected to microscopic
examinations. Cmab-mPA-uPA or Cmab-mPA-MMP combined with LD showed no outward or
histological signs of toxicity up to the highest doses (15 mg/kg) tested (Figure 2.2.6a), significantly
higher than any of the previously reported PA variants.
In order to study the pharmacokinetic properties of the Cmab-mPA variants, we labeled
wild-type PA, Cmab-mPA-uPA, or Cmab with radioactive 89Zr and injected mice (n = 4) intrave-
nously with 1 mg/kg of each protein. PET images acquired 6 h post injection showed similar bio-
distribution pattern between Cmab and Cmab-mPA-uPA, with some accumulation in liver and
significant portion still remained in circulation (Figure 2.2.6b). In contrast, most of the WT PA
was found in liver, indicating a fast clearance. In parallel, blood samples in different treatment
groups were collected at different time points for radioactivity measurements by gamma counter.
Consistent with PET imaging results, Cmab-mPA-uPA showed significantly prolonged clearance
time compared to the WT PA (Figure 2.2.6c).
In addition to Tmab and Cmab, we also conjugated mPA to Daclizumab as a mean to target
regulatory T cells. Due to time constraint, only proof-of-concept experiments were carried out.
Please see section 2.6.5 for detailed information.
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Figure 2.2.6. In vivo studies of Cmab-mPA variants. a) Microscopic appearance of kidney and
liver of mice 48 h after i.v. injection with PBS or 1 mg/kg of LD plus 15 mg/kg of Cmab-mPA
variants. b) Whole-body PET imaging of mice 6 h after i.v. injection of 89Zr-labeled wild-type PA,
Cmab, or Cmab-mPA-uPA (1 mg/kg). c) Comparison of relative blood concentration between
Cmab-mPA-uPA and wild-type PA. Blood samples (n=4) were taken at different time points and
measured for their radioactivity as described in the methods section. Relative %ID/g was normal-
ized to time 0.
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2.3. Discussion
Targeted intracellular protein delivery poses a major challenge since the vehicle needs to
not only reach the target site but also release the cargo into the cytosol. Monoclonal antibodies
possess the necessary versatility and clinical properties to be ideal targeting ligands. However,
their application in protein delivery has been limited due to its lack of endosomal release. In this
work, we report a novel targeted protein delivery platform by modularly combining IgG molecules
with the protein translocase PA through a chemical ligation strategy. We demonstrated the delivery
vehicle is entirely IgG-guided and requires the function of the translocase for activity. We used
this method to deliver proteins with a variety of functions, including ribosyltransferase DTA, ad-
enylate cyclase EF, and Ras protease RRSP.
Pathogenic bacteria often express toxins that are capable of delivering effector proteins
into the cytosol of cells. PA is a protein translocase used by Bacillus anthracis to deliver its cyto-
toxic payload lethal factor (LF). After nearly 40 years of extensive mechanistic and structural
studies, a model for PA-mediated protein translocation has been established. Biochemical and bi-
ophysical analyses have revealed how the N-terminal, PA-binding domain of LF (LFN) interacts
27
with the PA prepore to initiate protein translocation . Using PA/LFN as a delivery platform, we
and others have previously demonstrated its efficient cytosolic delivery of a wide variety of natural
and unnatural entities, including Pseudomonas exotoxin A (PE), P lactamase, dihydrofolate reduc-
tase, GFP, DARPin, L and D affibody, L and D peptides, etc76. Based on our in vitro pore formation
assay of IgG-mPA and the data on the delivery of three protein cargos with diverse functions, we
believe the translocation mechanism of the IgG-mPA system is similar to that of the wild type PA
and therefore should be compatible with the types of cargos that have previously been studied. The
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free combinations of different IgGs with protein cargos can potentially greatly expand the scope
of protein delivery.
When cancer cells are targeted for delivery, the payload is typically cytotoxic. Immuno-
toxins for example are protein toxins engineered to target cancer cells through ligands or antibod-
ies. However, they are often associated with dose-limiting toxicities as the result of off-target dam-
age to other tissues and cells 20,77. This is because most of the tumor cell surface antigens or recep-
tors are also present on normal cells and even a small amount of such toxins can cause serious
harm due to their catalytic nature7 8 . Here we took advantage of the protease-gated activation of
PA and the fact that most aggressive tumors require particular proteases such as uPA and MMPs
for the dissolution of extracellular matrix, which is a prerequisite for tumor invasion and metasta-
sis79,80. By replacing furin-dependent mPA with uPA- or MMP-dependent mPA variants in the
IgG-mPA conjugate, we created a highly specific delivery system that requires the simultaneous
presence of IgG-specific antigen and mPA-specific protease for activation. When we used a highly
potent toxin as the cargo of delivery, the dual-targeted system displayed significantly improved
selectivity compared to previous studies both in vitro and in vivo. Moreover, combinations of IgGs
and mPA variants needed little effort thanks to the modular design of the conjugation strategy,
which made the process easy and highly reproducible among different IgGs and mPAs. With an
enormous selection of monoclonal antibodies and many cell surface proteases expressed by human
cells and pathogens, we envision this delivery system can be easily tailored for a variety of dis-
eases.
One potential limitation with this delivery platform is that PA and LFN are both bacteria-
derived foreign proteins and therefore can induce antibody generation that limits their repeated
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dosages in a clinical setting. However, recent studies have found that an immunosuppressive reg-
imen that consists of pentostatin and cyclophosphamide (PC) can prevent the immunogenic re-
sponse against PA/LFN by depleting lymphocytes, particularly B cells, in immunocompetent
81,82C57BL/6J mice, . In addition, another group has reported induced immune tolerance to recom-
binant immunotoxins by co-administering them with nanoparticles containing rapamycin (SVP-
R)8 3'84. It is conceivable that the combination of IgG-mPA with these strategies will further im-
prove its utility as a protein drug delivery platform in a broad spectrum of diseases.
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2.4. Experimental
2.4.1. Materials
Fmoc-protected L- and D-amino acids used for peptide synthesis were purchased from
ChemImpex. Plasmids of Trastuzumab and Cetuximab were generously provided by Dr. Dane
Wittrup (Koch Institute for Integrative Cancer Research, Cambridge, MA). The plasmid encoding
LFN-RRSP was a generous gift from Dr. Karla Satchell (Northwestern University). All antibodies
used were purchased from Cell Signaling unless stated otherwise. All media used in cell culture
were purchased from Thermo Fisher.
2.4.2. Synthesis and purification of peptide linkers
Peptide linkers were synthesized on ChemMatrix resin with a Rink amide linker using ei-
ther manual flow peptide synthesis or automated flow peptide synthesizer as previously de-
scribed8 5' 86. The bromoacetamide or maleimide was coupled on resin as described in the supple-
mentary information. The crude peptides were cleaved by TFA/H20 (97.5:2.5) and purified by
semi-preparative RP-HPLC with Agilent Zorbax 300SB C18 column (9.4 x 250 mm, 5 um) at a
flow rate of 4 mL/min using the gradient of 1-31% acetonitrile over 80 min. Pure HPLC fractions
were subsequently pooled and analyzed by LC-MS (supplementary figure).
2.4.3. Construction of PA and IgG mutants
The plasmids of mPA (N682A, D683A), mPAC (N682A, D683A, K563C), and mPACA
(N682A, D683A, K563C, F427A) were prepared from wild type PA using QuickChange multi
site-directed mutagenesis kit (Agilent) according to the manufacturer's protocol. The furin cleav-
age site 164RKKR1 67 in mPAC was replaced by the uPA substrate sequence PGSGRSA or gelati-
nase substrate sequence GPLGMLSQ to give mPAC-uPA or mPAC-MMP using QuickChange
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single site-directed mutagenesis kit (Agilent). Using the same kit, the sortase-specific conjugation
tag LPSTGG was inserted at the C-terminus of the heavy chain of Trastuzumab and Cetuximab.
2.4.4. Expression and purification of PA mutants, EF, and LFN-RRSP
All non-IgG proteins were expressed in E. coli BL21 (DE3) cells from Thermo Fisher. The
expression of PA variants was done at New England Regional Center of Excellence/Biodefense
and Emerging Infectious Diseases (NERCE) and purified as previously described3 1 . In short, cell
pellet was first resuspended in sucrose buffer (20 mM Tris pH 8.5, 1 mM EDTA, 20% sucrose)
and then incubated with 5 mM MgSO 4 . The supernatant was purified by an anion exchange col-
umn, after which the pure fractions were pooled and concentrated based on the analysis of SDS-
PAGE. EF and LFN-RRSP were expressed in Champion PET-SUMO vector with a His tag in E.
coli BL21(DE3) and were induced at OD 0.7~0.9 with 0.4 mM IPTG at 20'C for 16 h. The proteins
were purified by a HisTrap FF Ni-NTA column. The SUMO was cleaved by SUMO protease and
removed by size exclusion chromatography.
2.4.5. Expression and purification of IgGs
Trastuzumab and cetuximab in gWiz vector were transiently transfected using PEI and
expressed in FreeStyle 293-F cells (Thermo Fisher) according to the manufacturer's protocol. The
IgGs were subsequently purified from the medium by Protein A affinity chromatography
(Genscript) and stored in PBS at -80*C.
2.4.6. Conjugation of mPA and IgGs
mPAC or its variants (400 uM) was first conjugated with the peptide linker (2 mM) in 20
mM Tris and 150 mM NaCl (pH 8.5). After the reaction went to completion in 1 h, the excess of
peptide was removed by three rounds of buffer exchange with 30K Amicon ultra-15 centrifugal
filter (Millipore). The resulted G3-mPA (100 uM) was incubated with IgG-LPSTGG (40 uM) in
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the presence of 5 uM of triple mutant sortase (SrtA*) in sortase buffer (50 mM Tris, 150 mM NaCl,
10 mM CaCl2, pH 7.5) for 1 h at room temperature. The reaction mixture was then loaded onto
HiLoad 16/600 Superdex 200 pg size exclusion column (GE). The fractions containing IgG-mPA
and IgG-(mPA) 2 were pooled and purified again by 5-mL HiTrap Q anion exchange column (GE)
to give pure IgG-mPA.
2.4.7. IgG-mPA stability
Cmab-mPA and Cmab-M-mPA prepared with bromoacetamide linker and maleimide
linker respectively were incubated in MEM supplemented with 10% FBS at 370 C. Samples from
different time points were analyzed by western blot using anti-PA antibody (Santa Cruz Biotech-
nology).
2.4.8. In vitro cleavage of Cetuximab-mPA variants by furin, uPA, and MMP-9
10 pig of different Cetuxiamb-mPA variants were incubated with 1 pl of furin (>2000
unit/ml, Sigma), 1 ptg of uPA (Millipore), or 0.2 ptg of MMP-9 (Millipore) in a total reaction vol-
ume of 40 pl. The cleavage reactions were performed in similar conditions as previously de-
scribed40 4 1 . Furin cleavage was done in 25 mM HEPES (pH 7.5), 150 mM NaCl, 0.2 mM EDTA,
0.2 mM EGTA, 1.0 mM CaCl2, and 1.0 mM MgCl 2. uPA cleavage was done in 20 mM Tris-HCl
(pH 7.5) and 150 mM NaCl. MMP-9 cleavage was carried out in 50 mM HEPES (pH 7.5), 10
mM CaCl 2, 200 mM NaCl, 0.05% (v/v) Brij-35, and 50 pM ZnSO 4. Aliquots at different time
points were analyzed by reducing SDS-PAGE using Bolt 4-12% Bis-Tris plus gel (Thermo Fisher).
2.4.9. Cell culture
All cell lines were purchased from American Type Culture Collection (Manassas, VA).
The cells were grown at 37'C in a 5% CO 2 environment. All cells were maintained according to
the instructions on ATCC except that MDA-MB-231 cells were grown in DMEM with 10% FBS.
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2.4.10. Cell viability assays
Cells were seeded in a 96-well plate at a density of 5x 103 per well and allowed to attach
overnight. The next day, the cells were treated with 10-fold serial dilutions of different protein
cargos with or without various IgG-PA variants for 72 h. The cell viability was measured by
CellTiter-Glo luminescent assay (Promega) following the manufacturer's protocol. The relative
viability was normalized to cells without treatment.
2.4.11. cAMP assay
MDA-MB-231 cells (1.5x 104) were plated in a 96-well plate on the previous day of treat-
ment. Cells were incubated with 20 nM EF or LD in the presence or absence of 100 nM different
IgG-mPA variants for 2 h. Cells were lysed in 0.1 M HCl with 0.5% Triton X-100. A colorimetric
competitive ELISA kit (Enzo Life Science) was used to measure the intracellular cAMP levels
according to the manufacturer's instructions.
2.4.12. Western blotting
MDA-MB-231 cells were plated at 2x 105 cells/well in a 12-well plate. After 24 h, the cells
were treated with 50 nM LFN-RRSP (LR) in the presence or absence of different IgG-mPA variants
for another 24 h. Subsequently, the medium was removed and the cells were lysed by RIPA buffer
(10 mM pH 8.0 Tris-Cl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS,
140 mM NaCl, 1 mM PMSF) supplemented with Roche protein inhibitor for 20 minutes on ice.
The lysate was separated by SDS-PAGE and transferred onto a PVDF membrane (Bio-Rad) using
a Bio-Rad Trans-Blot turbo transfer system. The membrane was blocked with LI-COR blocking
buffer on a shaker at room temperature for I h before the membrane was incubated with different
primary antibodies in TBST buffer and 0.1% Tween overnight at 4'C. On the next day, the mem-
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brane was washed by TBST three times and then incubated with the appropriate fluorescent sec-
ondary antibody in TBST on a shaker for 1 h at RT. The imaging was done by ChemiDoc MP
imaging system (Bio-Rad). Serial detection of proteins was done by stripping the membrane with
stripping buffer (Thermo Fisher) and repeating the above staining procedure.
2.4.13. Histopathological analysis
All animal work was conducted in accordance with a protocol approved by the MIT Com-
mittee on Animal Care. We used a dose-escalation protocol to characterize the potential toxicity
of LD in combination with dual-targeting Cetuximab-mPA variants. Female nude mice between 8
to 12 weeks (n = 3) were anesthetized by isoflurane inhalation and injected intravenously with
either a single dose of vehicle PBS or LD (1 mg/kg). For combination dose, a second injection
was performed to administer the 3 mg/kg or 15 mg/kg of Cetuximab-mPA-uPA or Cetuximab-
mPA-MMP. The mice were closely monitored for any signs of toxicity. After 48 h, the mice were
euthanized, tissues were fixed in 4% formalin, embedded in paraffin, and sections were stained
with hematoxylin and eosin (H&E) for microscopic analysis by a pathologist.
2.4.14. PK study
Female nude mice between 8 to 12 weeks were injected i.v. through the tail vain with wild
type PA or Cetuximab-mPA-uPA labeled with 89Zr (Washington University School of Medicine
in St. Louis) at 1 mg/kg (n = 4). 5-15 mg of blood samples at indicated time points were collected
by tail snipping and the radioactivity was measured by PerkinElmer Wizard 2 gamma counter. The
PET scans were acquired on a G8 PET/CT preclinical imaging system (PerkinElmer). After 166
h, the mice were sacrificed by CO 2 followed by cervical dislocation. The organs and tissues were
collected and measured by the gamma counter.
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2.6. Appendix
2.6.1. Amino acid sequences of mPAC and mPACA
PA[N682A, D683A, K563C] (mPAC)
MEVKQENRLLNESESSSQGLLGYYFSDLNFQAPMVVTSSTTGDLSIPSSELENIPSENQYF
QSAIWSGFIKVKKSDEYTFATSADNHVTMWVDDQEVINKASNSNKIRLEKGRLYQIKIQ
YQRENPTEKGLDFKLYWTDSQNKKEVISSDNLQLPELKQKSSNSRKKRSTSAGPTVPDR
DNDGIPDSLEVEGYTVDVKNKRTFLSPWISNIHEKKGLTKYKSSPEKWSTASDPYSDFEK
VTGRIDKNVSPEARHPLVAAYPIVHVDMENIILSKNEDQSTQNTDSETRTISKNTSTSRTH
TSEVHGNAEVHASFFDIGGSVSAGFSNSNSSTVAIDHSLSLAGERTWAETMGLNTADTA
RLNANIRYVNTGTAPIYNVLPTTSLVLGKNQTLATIKAKENQLSQILAPNNYYPSKNLAPI
ALNAQDDFSSTPITMNYNQFLELEKTKQLRLDTDQVYGNIATYNFENGRVRVDTGSNW
SEVLPQIQETTARIIFNGKDLNLVERRIAAVNPSDPLETTKPDMTLKEALKIAFGFNEPNG
NLQYQGKDITEFDFNFDQQTSQNICNQLAELNATNIYTVLDKIKLNAKMNILIRDKRFHY
DRNNIAVGADESVVKEAHREVINSSTEGLLLNIDKDIRKILSGYIVEIEDTEGLKEVINDR
YDMLNISSLRQDGKTFIDFKKYAAKLPLYISNPNYKVNVYAVTKENTIINPSENGDTSTN
GIKKILIFSKKGYEIG
PA[N682A, D683A, K563C, F427A] (mPACA)
MEVKQENRLLNESESSSQGLLGYYFSDLNFQAPMVVTSSTTGDLSIPSSELENIPSENQYF
QSAIWSGFIKVKKSDEYTFATSADNHVTMWVDDQEVINKASNSNKIRLEKGRLYQIKIQ
YQRENPTEKGLDFKLYWTDSQNKKEVISSDNLQLPELKQKSSNSRKKRSTSAGPTVPDR
DNDGIPDSLEVEGYTVDVKNKRTFLSPWISNIHEKKGLTKYKSSPEKWSTASDPYSDFEK
VTGRIDKNVSPEARHPLVAAYPIVHVDMENIILSKNEDQSTQNTDSETRTISKNTSTSRTH
TSEVHGNAEVHASFFDIGGSVSAGFSNSNSSTVAIDHSLSLAGERTWAETMGLNTADTA
RLNANIRYVNTGTAPIYNVLPTTSLVLGKNQTLATIKAKENQLSQILAPNNYYPSKNLAPI
ALNAQDDASSTPITMNYNQFLELEKTKQLRLDTDQVYGNIATYNFENGRVRVDTGSNW
SEVLPQIQETTARIIFNGKDLNLVERRIAAVNPSDPLETTKPDMTLKEALKIAFGFNEPNG
NLQYQGKDITEFDFNFDQQTSQNICNQLAELNATNIYTVLDKIKLNAKMNILIRDKRFHY
DRNNIAVGADESVVKEAHREVINSSTEGLLLNIDKDIRKILSGYIVEIEDTEGLKEVINDR
YDMLNISSLRQDGKTFIDFKKYAAKLPLYISNPNYKVNVYAVTKENTIINPSENGDTSTN
GIKKILIFSKKGYEIG
*The Furin cleavage sites are highlighted in blue and the mutated residues are highlighted in red.
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Figure 2.6.1. The SDS-PAGE analyses of anion exchange chromatography of mPAC (N682A,
D683A, K563C), and mPACA (N682A, D683A, K563C, F427A). The gels were overloaded due
to the high protein concentration. Suc is the supernatant from sucrose buffer resuspension. Mg is
the supernatant from Mg buffer extraction.
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Figure 2.6.2. Deconvoluted mass traces of mPAC and mPACA from LC-MS. 200 ng of each
protein was injected into Zorbax 300SB C3 column with a method of 5-65% acetonitrile over 15
minutes. The TIC peak was integrated and the mass was deconvoluted using maximum entropy
algorithm.
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Figure 2.6.3. LC-MS traces of the peptide linkers used in this study. D-amino acids are indi-
cated by the lowercase letters. Maleimide (Me) was coupled on the side chain of L- or D-lysine by
treating the resin with 1.5 equivalents of N-y-maleimidobutyryl-oxysuccinimide ester (GMBS,
Thermo Fisher) dissolved in DMF for 3 h after lysine deprotection. Similarly, Br was coupled by
incubating the resin with 0.4 M bromoacetic acid, 0.38 M HATU, and 0.38 M DIEA in DMF for
20 minutes.
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2.6.2. Amino acid sequence of Trastuzumab
Trastuzumab-LC
ADIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGV
PSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSST
LTLSKADYEKHKV YACEVTHQGLSSPVTKSFNRGEC
Trastuzumab-HC
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYT
RYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGT
LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP
AVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPA
PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV
YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS
KLTVDKSRWQQGNVFSCSVMHEALHNIHYTQKSLSLSPGK
Trastuzumab-HC-LPSTGG
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYT
RYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGT
LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP
AVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPA
PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV
YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS
KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPLPSTGGK
*The LPSTG insertion is highlighted in red.
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2.6.3. Amino acid sequence of Cetuximab
Cetuximab-LC
DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFS
GSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDE
QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLS
KADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Cetuximab-HC
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTD
YNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVT
VSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE
LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR
EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL
PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT
VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Cetuximab-HC-LPSTGG
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTD
YNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVT
VSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE
LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR
EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL
PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT
VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPLPSTGGK
*The LPSTG insertion is highlighted in red.
104
LC
obs. 23511.21
calc. 23514.17
Trastuzumab-HC-LPSTGG
I
HC-LPSTGG
obs. -51018.47
calc. 49708.10
3000 4'000 5dooo 6600
Deconvoluted Mass (amu)
7000 8'000 9000
LC
obs. 23423.35
calc. 23426.95
Cetuximab-HC-LPSTGG
H
0
c
15000 2'000 25000 3d000 35000 4'000 45000
Deconvoluted Mass (amu)
C-LPSTGG
bs. -52504.53
alc. 49767.18
5'000 55000 6000
Figure 2.6.4. The LC-MS deconvoluted masses of the light chains (LCs) and heavy chains
(HCs) of Trastuzumab-HC-LPSTGG and Cetuximab-HC-LPSTGG. The IgGs were reduced
by 20 mM TCEP in PBS at 37'C for 20 minutes before LC-MS analysis. The mass difference and
heterogeneity of the HCs was due to post translational modification.
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Figure 2.6.5. LC-MS deconvoluted masses of mPAs conjugated with different peptide link-
ers. The conjugations were performed as described in the methods section. 200 ng of each protein
was injected into Zorbax 300SB C3 column with a method of 5-65% acetonitrile over 15 minutes.
The TIC peak was integrated and the mass was deconvoluted using maximum entropy algorithm.
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Figure 2.6.6. SDS-PAGE analysis of Cmab-mPA prepared as described in the methods sec-
tion. In short, Cmab-HC-LPSTGG was reacted with three equivalents of G 3-mPA in the presence
of SrtA*. After 1 h at RT, the reaction mixture was sequentially purified by size exclusion and
anion exchange chromatography to give pure Cmab-mPA.
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Figure 2.6.7. In vitro SDS-resistant pore formation assay analysed by SDS-PAGE. The SDS-
resistant pore formation assay was performed as described previously. Mixture of Tmab-(mPA) 2
and Tmab-mPA (lane 1) was first nicked by Trypsin and purified by anion exchange chromatog-
raphy (lane 2). The resulted mixture of Tmab-(mPA 63)2 and Tmab-mPA 63 were incubated with
Tris or MES buffers at different pHs for 30 minutes at RT and then resolved by SDS-PAGE. Pro-
tein bands were visualized by Coomassie blue staining.
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Figure 2.6.8. Stability comparison between IgG mPA conjugates with different linkers. An-
tibody mPA conjugates prepared with bromoacetamide linker (IgG-mPA) or maleimide linker
(IgG-M-mPA) was incubated in MEM with 10% fetal bovine serum at 37 C for a week. Samples
were taken from indicated time points and analyzed by anti-PA western blot. IgG-M-mPA showed
significant degradation whereas IgG-mPA mostly remained intact. Trastuzumab is used in this
experiment.
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Figure 2.6.9. Activity comparison between Tmab-mPA, Tmab-M-mPA, Tmab-(GGS) 7-M-
mPA. BT474 cells were treated with 10 nM LD and different Tmab-mPA variants for 72 h before
being subject to CellTiter-Glo. The relative viability is normalized to no treatment. Each data point
is a triplicate.
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Figure 2.6.10. Activity comparison between Tmab-mPA and Tmab-(mPA) 2 in the presence
of 10 nM LD.
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Figure 2.6.11. SEC purification of Cmab-M-(mPAC). analyzed by SDS-PAGE. Cmab was
first reacted with 50 equivalents of SM(PEG)4 (Thermo Fisher) dissolved in DMSO for 1 h at RT
(lane 1). The extra linker was then removed by buffer exchange. The resulted Cmab was incubated
with 40 equivalents of mPAC for 1 h at RT (lane 2) before separation by size exclusion. The
average number of mPA per antibody was calculated to be about 7 based on final yield of the
reaction assuming the antibody is 100% recovered after purification.
112
1.2-
1.0-
0.8-
0.6-
0.4-
0.2-
0.0-
5 -14 -13 -12 -11 -10 -9 -8 -7 -6
Log concentration (M)
Figure 2.6.12. Activity comparison between Cmab-mPA and Cmab-M-(mPA).. A549 cells
were treated with both proteins at the indicated concentrations in the presence of 10 nM LD for 72
h. The cell vability was measured by CellTiter-Glo and normalized to no treatment group. Each
data point is a triplicate.
113
CU
-u- Cmab-mPA
-e-- Cmab-M-(mPA),
... Siza.e exusione fractions.
198 KDa! 3- 
- *m a"
98 KDaZI
62 KDa
49 KDa
38 KDa
28 KDa
- Tmab-(LD)2
- Tmab-LD
+- Tmab-HC-LPSTGG
+- G5-LD
+ SrtA*
Figure 2.6.13. SDS-PAGE analysis of Tmab-LD purified by SEC. Tmab-LD was prepared sim-
ilarly to IgG-mPA. Tmab-HC-LPSTGG was reacted with 5 equivalents of G5-LD in the presence
of SrtA* (lane 1) for 30 minutes at RT before purification by size exclusion chromatography.
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Figure 2.6.14. Viability of BT549 and Jurkat cells treated with WT PA in the presence of LD.
Cells were treated with 10-fold serial dilutions of wild-type PA in the presence of 10 nM of LD.
Viability was measured after 72 h by CellTiter-Glo as described in the methods section.
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Figure 2.6.15. Different responses to Cmab-mPA and Tmab-mPA in the presence of 10 nM
of LD in different cell lines. The cells were treated with 10-fold serial dilutions of Cmab-mPA or
Tmab-mPA with 10 nM of LD. Viability was measured by CellTiter-Glo as described in the meth-
ods section.
116
0.2-
V.V I ! . i .
2.6.4. Amino acid sequence of mPAC-uPA and mPAC-MMP
mPAC-uPA
MEVKQENRLLNESESSSQGLLGYYFSDLNFQAPMVVTSSTTGDLSIPSSELENIPSENQYF
QSAIWSGFIKVKKSDEYTFATSADNHVTMWVDDQEVINKASNSNKIRLEKGRLYQIKIQ
YQRENPTEKGLDFKLYWTDSQNKKEVISSDNLQLPELKQKSSNSPGSGRSASTSAGPTV
PDRDNDGIPDSLEVEGYTVDVKNKRTFLSPWISNIHEKKGLTKYKSSPEKWSTASDPYSD
FEKVTGRIDKNVSPEARHPLVAAYPIVHVDMENIILSKNEDQSTQNTDSETRTISKNTSTS
RTHTSEVHGNAEVHASFFDIGGSVSAGFSNSNSSTVAIDHSLSLAGERTWAETMGLNTA
DTARLNANIRYVNTGTAPIYNVLPTTSLVLGKNQTLATIKAKENQLSQILAPNNYYPSKN
LAPIALNAQDDFSSTPITMNYNQFLELEKTKQLRLDTDQVYGNIATYNFENGRVRVDTG
SNWSEVLPQIQETTARIIFNGKDLNLVERRIAAVNPSDPLETTKPDMTLKEALKIAFGFNE
PNGNLQYQGKDITEFDFNFDQQTSQNICNQLAELNATNIYTVLDKIKLNAKMNILIRDKR
FHYDRNNIAVGADESVVKEAHREVINSSTEGLLLNIDKDIRKILSGYIVEIEDTEGLKEVIN
DRYDMLNISSLRQDGKTFIDFKKYAAKLPLYISNPNYKVNVYAVTKENTIINPSENGDTS
TNGIKKILIFSKKGYEIG
mPAC-MMP
MEVKQENRLLNESESSSQGLLGYYFSDLNFQAPMVVTSSTTGDLSIPSSELENIPSENQYF
QSAIWSGFIKVKKSDEYTFATSADNHVTMWVDDQEVINKASNSNKIRLEKGRLYQIKIQ
YQRENPTEKGLDFKLYWTDSQNKKEVISSDNLQLPELKQKSSNSGPLGMLSQSTSAGPT
VPDRDNDGIPDSLEVEGYTVDVKNKRTFLSPWISNIHEKKGLTKYKSSPEKWSTASDPYS
DFEKVTGRIDKNVSPEARHPLVAAYPIVHVDMENIILSKNEDQSTQNTDSETRTISKNTST
SRTHTSEVHGNAEVHASFFDIGGSVSAGFSNSNSSTVAIDHSLSLAGERTWAETMGLNT
ADTARLNANIRYVNTGTAPIYNVLPTTSLVLGKNQTLATIKAKENQLSQILAPNNYYPSK
NLAPIALNAQDDFSSTPITMNYNQFLELEKTKQLRLDTDQVYGNIATYNFENGRVRVDT
GSNWSEVLPQIQETTARIIFNGKDLNLVERRIAAVNPSDPLETTKPDMTLKEALKIAFGFN
EPNGNLQYQGKDITEFDFNFDQQTSQNICNQLAELNATNIYTVLDKIKLNAKMNILIRDK
RFHYDRNNIAVGADESVVKEAHREVINSSTEGLLLNIDKDIRKILSGYIVEIEDTEGLKEVI
NDRYDMLNISSLRQDGKTFIDFKKYAAKLPLYISNPNYKVNVYAVTKENTIINPSENGDT
STNGIKKILIFSKKGYEIG
*The Furin cleavage sites are replaced by uPA and MMP substrate sequences as highlighted in
blue and the mutated residues are highlighted in red.
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Figure 2.6.16. SDS-PAGE analysis of mPAC-uPA and mPAC-MMP purified by anion ex-
change chromatography.
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Figure 2.6.17. Deconvoluted mass traces of mPAC-uPA and mPAC-MMP from LC-MS. 200
ng of each protein was injected into Zorbax 300SB C3 column with a method of 5-65% acetonitrile
over 15 minutes. The TIC peak was integrated and the mass was deconvoluted using maximum
entropy algorithm.
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Figure 2.6.18. Deconvoluted masses of G3llk-mPAC-uPA and G3llk-mPAC-MMP.
conjugation to mPAC variants was performed as described in the methods section.
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Figure 2.6.19. SDS-PAGE analysis of Cmab-mPA-uPA purification. Cmab-mPA-uPA was
prepared as described in the methods section. In short, Cmab-HC-LPSTGG was reacted with three
equivalents of G3-mPA-uPA in the presence of SrtA*. After I h at RT, the reaction mixture was
sequentially purified by size exclusion and anion exchange chromatography to give pure Cmab-
mPA-uPA.
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Figure 2.6.20. SDS-PAGE analysis of Cmab-mPA-MMP purification. Cmab-mPA-MMP was
prepared as described in the methods section. In short, Cmab-HC-LPSTGG was reacted with three
equivalents of G 3-mPA-MMP in the presence of SrtA*. After 1 h at RT, the reaction mixture was
sequentially purified by size exclusion and anion exchange chromatography to give pure Cmab-
mPA-MMP.
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LD (1 mg/kg)
+ Cmab-mPA-MMP (3mg/kg)
Figure 2.6.21. Histological analysis of kidney and liver tissues from mice injected with 1
mg/kg of LD alone or in combination with Cmab-mPA-uPA or Cmab-mPA-MMP (1 mg/kg).
The tissue samples were prepared as described in the methods section.
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Figure 2.6.22. Change of biodistribution of different proteins over time. Whole-body PET
images were acquired as described in the methods section. Shorter time scale was used for wild-
type PA due to its rapid clearance time.
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Figure 2.6.23. Tissue distribution of Cmab and Cmab-mPA-uPA 166 h post injection. Tissues
from different organs were measured for radioactivity as described in the methods section.
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Figure 2.6.24. Tissue distribution of WT PA 24 h post injection. Tissues from different organs
were measured for radioactivity as described in the methods section.
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2.6.5. Targeting of activated T cells by LD delivered by Daclizumab-mPA
Great progress has been made in taking advantage of immune system to suppress tumor in
the past decade. But at the same time, new challenge has emerged that it is difficult to effectively
evoke autoimmunity. Accumulating evidence indicates depleting Treg cells can elicit strong anti-
tumor immune response. Here we report a novel approach to target and remove Treg cells by using
our IgG-mPA system directed by Daclizumab (Dmab), an IgG molecule that binds to CD25, the
alpha subunit of the IL-2 receptor of Treg cells. We investigated the ability of Dmab-mPA to
deliver LD into activated Jurkat cells. Compared with Dmab only, Dmab-mPA with LD was able
to significantly reduce viability of Jurkat cells. Surprisingly, Dmab-mPA itself was also toxic to
activated Jurkat cells. One explanation is that the oligomerization of CD25 mediated by Dmab-
mPA on cell surface might have an effect on the viability of the Jurkat cells. Another possibility
is that the pore-forming Dmab-mPA significantly permeablized the endosome and caused toxicity.
Relative viability of activated Jurkat cells
(72 h treatment)
2.5
2
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0.5
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Dmab Dmab-S-mPA Dmab-S-mPA + LD
N 10 nM * 100 nM
Figure 2.6.25. Relative viability of activated Jurkat cells treated with Dmab-mPA + LD and
other controls. Jurkat cells were seeded in a 96-well v-bottom plate at a density of 2x 104 per well
and activated by Wash Dynabeads from Life Technologies according to the manufacturer's in-
structions. 2x 104 Jurkat cells with 50 iL medium were incubated with 2 pL of pre-washed and
resuspended Dynabeads in a humidified CO2 incubator at 37*C for 24 h. After activation, Jurkat
cells were treated 10-fold serial dilutions of different Dmab, Dmab-mPA, or Dmab-mPA + LD for
72 h. The cell viability was measured as described in the methods section.
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Chapter 3: Single-component anthrax delivery system enabled by
chemical conjugation
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3.1. Introduction
Anthrax toxin is a bacterial toxin from Bacillus anthracis. It consists of two effector pro-
teins, lethal factor (LF)' and edema factor (EF)2, and a translocase, protective antigen (PA) 3. Over
the past 40 years, extensive biochemical and biophysical research has shed light on how these
individual components act together to fulfill the biological function of anthrax toxin. Once the
toxin is released by the bacteria, PA binds to two receptors on cell surface with nanomolar or
picomolar affinity 4-6. The bound PA is subsequently cleaved by cell-surfce furin to a 63 kDa form
(PA63)7 and oligomerizes into the PA heptameric or octameric prepore8 ', which three or four LF
or EF molecules dock to with high affinity' 0 '. The entire complex is then endocytosed and the
acidic pH in the endosome converts the prepore into transmembrane pore by triggering its confor-
mational rearrangement'2-14. The pore translocates the LF or EF molecules to the cytoplasm, where
the effector proteins catalyze their respective reactions 2 15 .
Previous findings have revealed that the N-terminal domain of LF (LFN, residues 1-254)
interacts with two adjacent subunits of the PA prepore and is responsible for initiating PA-
mediated translocation. Mechanistic studies show that key electrostatic interactions between the
first a-helix and P-sheet of LFN and PA help partially unfold the N-terminal region of the protein
and poise it for N- to C-terminal translocation". Based on these findings, a variety of cargos have
been fused to the C-terminus of LFN and translocated via PA. These cargos include beta-lac-
tamasel , Diphtheria toxin A (DTA) 7, Pseudomonas exotoxin A1 8 , Ras protease RRSP' 9 , etc. In
addition, antibody mimics20 as well as non-natural entities such as mirror image polypeptides and
proteins2 have also been delivered into cells using the LFN/PA system.
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Since the function of LFN can be dissected into co-localizing the cargo to the PA pore and
facilitating the subsequent translocation, it is conceivable that this function may be partially re-
placed by covalent conjugation of the cargo protein to PA. In this study, we ligated the cargo
protein with or without LFN directly to PA through a specific sortase-mediated reaction. We also
investigated the effect of fusing the cargo protein with an N-terminal polylysine tag, which has
been previously shown to facilitate PA-dependent translocation . Our results demonstrate that
in the absence of LFN, the chemically generated single-component cargo-PA conjugate with ap-
propriate linker significantly enhanced delivery efficiency compared to the traditional dual-com-
ponent system.
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3.2. Results
3.2.1. Design of single-component anthrax system
A common strategy to combine two proteins together is recombinant expression. However,
this strategy only allows one protein to be fused at the N- or C-terminus of the other protein. During
the mechanism of PA, the C-terminal domain needs to bind to cell surface receptors and the N-
terminal PA20 domain needs to be proteolytically cleaved by furin protease for activation. There-
fore, recombinant expression of the cargo protein with PA risks disruption of the function of PA
or the cargo protein.
We sought to use chemical conjugation as an alternative strategy to attach a cargo protein
to PA. A previously known functional PA mutant PA[K563C] (PAC) was first prepared by recom-
binant expression in Escherichia coli B121(DE3) and purified with anion exchange chromatog-
raphy. Two different peptides, one short D-peptide and one long L-peptide, were synthesized using
Fmoc chemistry, each with an N-terminal triglycine and a C-terminal maleimide (Figures 3.2.1 b
and 3.6.1). The linkers were designed with different stabilities in the endosome with the long one
susceptible to endosomal protease cathepsin B2 and this was to test the cleavage requirement of
the cargo protein. The peptides were then conjugated to a cargo protein with a C-terminal LPSTGG
recognition motif via sortase-mediated ligation using an evolved sortase (SrtA*) 2 8. The resulting
maleimide-containing protein was purified and covalently ligated again to PAC through thiol-ma-
leimide coupling. The product mixture was separated by size exclusion chromatography to give
homogeneous protein-PA conjugate (Figures 3.2. lc-e).
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Figure 3.2.1. Design and preparation of the single-component anthrax delivery system. a)
Mechanism of LFN/PA-mediated translocation. b) Schematic showing the design of cargo protein-
PA conjugate with two different linkers. Linker1 and linker2 contain either L- or D-amino acids
respectively. Both linkers have N-terminal triglycine tag and C-terminal maleimide for conjuga-
tion. c) Cargo protein with a C-terminal LPSTGG tag was labeled with one of the peptide linkers
via sortase-mediated ligation and then attached to PAC through maleimide-thiol coupling. The
final product was purified by size exclusion chromatography. d) LC-MS deconvoluted mass traces
of a representative protein cargo DTA conjugated to PA via peptide linker1. e) SDS-PAGE anal-
ysis of DTA-linkerl-PA purification by size exclusion chromatography.
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3.2.2. Single-component anthrax delivery system showed significant activity.
Diphtheria toxin A chain (DTA) is the catalytic domain of diphtheria toxin, which ribosyl-
ates the eukaryotic elongation factor 2 (EF-2) with ADP. Although it is non-toxic by itself, it be-
comes an extremely potent protein toxin upon cytosolic delivery. Its delivery by the LFN/PA sys-
tem has been extensively characterized and has been used as the "gold standard" assay for PA-
mediated cytosolic translocation in previous studies. We used DTA as the reporter protein to study
the activity of the single-component anthrax-mediated delivery system due to its robust effect on
cell viability.
We first investigated whether the PA delivery system can still be functional when the LFN
cargo protein conjugate is directly attached to PA. LFN-DTA-LPSTGG (LD) was ligated to PAC
with the two different peptide linkers and purified as described above (Figure 3.2.2a). HeLa cells
were plated in 96-well plate and treated with 5-fold serial dilutions of different proteins. After 72
h, the efficiency of the delivery was measured by the change of cell viability, which correlates to
the amount of translocated DTA. We hypothesized that the cargo LD can be released from PA and
translocated in case of the longer L-linker2 due to its susceptibility to cleavage in endosome,
whereas the less vulnerable shorter D-linkerl should have a lower delivery efficiency. However,
to our surprise, both LD-linkerl-PA and LD-linker2-PA displayed highly efficient delivery of
DTA, with LD-linkerl-PA more active than LD-linker2-PA and almost as active as LD + PA
(Figure 3.2.2b). LD protein by itself did not cause any cell death as expected, confirming this
process is PA-dependent. While this observation may indicate both peptide linkers can be cleaved
in endosome prior to translocation, it is also possible that LD is getting released in the medium
especially considering the known instability of maleimide in serum.
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In order to study whether the translocase function of PA is required for the delivery of
DTA, we also conjugated LD to PA[F427A] (PAA), a mutant PA that's incapable of translocation
but maintains the other functions. As expected, we found that PAA arrested translocation in both
single-component LD-linkerl -PAA and two-component LD + PAA (Figure 3.2.2c), indicating the
translocation is mediated by the translocase activity of PA.
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Figure 3.2.2. Delivery of LFN-DTA (LD) mediated by the single-component anthrax system.
a) Design of single-component LD-PA conjugate. b) Relative viability of HeLa cells after treat-
ment with different proteins. The cells were incubated with 5-fold serial dilutions of LD-linkerl -
PA (IC5 0 = 4.71 x 10~" M), LD-linker2-PA (IC50 = 1.22 x 10-' 0 M), and positive control LD + PA
(IC50 = 5.27 x 10-10 M), or negative control LD for 72 h. The cell viability was measured by
CellTiter-Glo assay and normalized to the group with no treatment. In the case of LD + PA,
equimolar of LD and PA were used and diluted simultaneously to keep a 1:1 ratio. c) Cells were
treated with LD conjugated to PA[F427A] (PAA), a translocation-deficient mutant of PA, under
the same conditions. Each data point represents a triplicate.
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3.2.3. Single-component anthrax delivery system has significantly improved activity in the
absence of LFN.
Past biophysical and biochemical studies have shed light on the two-fold function of the
first 254 residues of lethal factor LFN: 1. It cO-localizes the cargo protein with PA by binding to
the PA prepore through its interaction with two adjacent subunits of the oligomer; 2. It also initiates
translocation by partially unfolding its N-terminal region and poising the protein for translocation
from N- to C-terminus.
Based on the activity data of LD-PA, we wanted to study whether the function of LFN Can
be partially replaced by co-localizing the cargo protein with PA through chemical ligation. DTA-
LPSTGG was conjugated to PAC using the same method as described above (Figure 3.2.3a). HeLa
cells were incubated with 5-fold serial dilutions of DTA-linkerl-PA or DTA-linker2-PA for 72 h
and the cell viability was measured by CellTiter-Glo. Both conjugates exhibited much more en-
hanced activity when compared to the control of separate DTA and PA (Figure 3.2.3b). DTA by
itself did not show any activity even at the highest concentration used. In comparison, DTA-PAA
conjugates of different linkers as well as DTA + PAA failed to inhibit cell growth (Figure 3.2.3c).
Taken together, these data suggest covalent attachment of cargo protein to PA partially restores
the function of LFN and significantly improve the delivery efficiency of the cargo. These results
also indicate the cleavage of the maleimide was not significant enough to mask the effect of co-
localization, since the free DTA is much less potent than the single-component in the presence of
PA. One possible explanation for the superior activity of DTA-linkerl -PA to DTA-linker2-PA is
the longer and more flexible linker2 led to intramolecular DTA-PA interaction, which inhibited
one or a few steps during the mechanism of PA translocation.
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Figure 3.2.3. Delivery of DTA in the absence of LFN. a) Design of DTA-PA conjugate. DTA
without the N-terminal LFN was conjugated directly to PA. b) Relative viability of HeLa cells
after incubation with DTA-PA. HeLa cell were treated with 5-fold serial dilutions of DTA-linkerl-
PA (IC5 0 = 3.32 x 10-9 M), DTA-linker2-PA (IC50 = 8.14 x 10~9 M), and DTA +PA (IC 50 = 3.38 x
10-8 M) for 72 h before subject to CeillTiter-Glo assay. c) Relative viability of HeLa cells after
treatment with DTA-PAA. Cells were treated with DTA-PAA conjugates under the same condi-
tions and measured for their relative viability. Each data point is a triplicate.
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3.2.4. N-terminal polylysine further improves the efficiency of the single-component system.
It has been reported previously that N-terminal polylysine tag can mediate translocation
through the PA pore. Here we investigated whether an N-terminal Lys tag can further potentiate
the activity of the single-component PA delivery system. K5DTA-LPSTGG was conjugated to
PAC using the same strategy as described above (Figure 3.2.4a). We treated HeLa cells with serial
dilutions of K5DTA-PA conjugates with K5DTA + PA as the control. We found that separate
K5DTA and PA increased the delivery efficiency by nearly 10-fold compared to without the K5
tag, consistent with the previous finding (Figure 3.2.4b). More importantly, the single-component
K5DTA-linkerl -PA further increased the activity by nearly another order of magnitude, in good
agreement with our hypothesis. On the other hand, K5DTA-linker2-PA failed to show any signif-
icantly enhanced delivery compared to the two-component system or DTA-linker2-PA. This might
be due to stronger nonspecific interaction between K5DTA and PA caused by the polycationic tag.
To confirm the delivery is still PA-dependent, we again conjugated K5DTA to PAA and treated
HeLa cells under the same condition. Neither KsDTA-linkerl-PAA or K5DTA-linker2-PAA
showed any antiproliferative effect even at the highest concentration tested (Figure 3.2.4c). Simi-
larly, co-treatment of K5DTA and PAA also had little impact on the cell growth. Taken together,
these results indicate the covalent conjugation strategy with proper linker significantly improves
the delivery efficiency of polylysine tagged cargo protein. They also suggest that the K5 tag con-
tributed more to the initiation of translocation than to the binding to PA since it increased the
activity of the unconjugated system by about the same extent as the conjugated system.
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Figure 3.2.4. Delivery of polylysine tagged DTA with the single-component system. a) Sche-
matic representation of K5DTA-PA. The N-terminal K5 tag was fused to DTA by recombinant
expression. b) Relative viability of HeLa cells treated with K5DTA-linkerl-PA (IC50 = 6.40 x 10~
10 M), K5DTA-linker2-PA (IC50 = 3.74 x 10~ M), and K5DTA + PA (IC50 = 3.89 x 10-' M) for 72
h. c) Relative viability of HeLa cells after 72-h K5DTA-PAA or K5DTA + PAA treatment. The
cell viability was measured by CellTiter-Glo and normalized to untreated cells. Each data point is
a triplicate.
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3.3. Discussion
Here we report a novel single-component anthrax delivery system that can significantly
enhance the delivery efficiency of the protein cargo in the absence of LFN. The single-component
system was generated by conjugating the cargo protein, which is labeled with C-terminal malei-
mide by sortase-mediated ligation, site-specifically to the sole cysteine in PAC via maleimide-
thiol crosslinking to give a homogeneous product with an exact cargo-to-PA ratio of one. Another
alternative would be to use a non-specific conjugation strategy such as a bifunctional linker with
NHS ester and maleimide. Although this approach could potentially increase the cargo load per
PA molecule, it only works when the cargo protein has no cysteine, which severely limits its ap-
plication. Moreover, some conjugated cargos could be near places that are important for PA func-
tion, such as the receptor binding region or the interface between subunits during oligomerization.
When we sought out to design the single-component PA delivery system, our goal was to
engineer it so that the cargo protein is only released from PA in the endosome. For this purpose,
two linkers were synthesized, a long poly-GGS linker (linker2) that is susceptible to cleavage by
the endosomal protease cathepsin B24 and a short D-peptide linker (linkerl) as a non-cleavable
control. In order to test the cleavabilities of the poly-GGS linker, we conjugated LD to PA using
both linkers and hypothesized that only LD-linker2-PA would be active. However, to our surprise,
both conjugates displayed efficient delivery of LD within one order of magnitude to LD + PA.
With this observation, we came up with three possible explanations: 1. Both linkers can be cleaved
efficiently in the endosome due to its harsh environment. 2. Both linkers were cleaved in the me-
dium due to the reported instability of maleimide 2 5 and the observed activity completely came
from the LD released outside of cell. 3. LD-PA conjugate can translocate and the linker cleavage
is not required.
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In order to investigate whether the single-component system is truly effective, we removed
LFN and conjugated DTA directly to PA. Since DTA does not translocate through PA very well,
if it is cleaved outside of cell, DTA-PA should have comparable activity to DTA + PA. Moreover,
if there is no cleavage, DTA-PA should not perform better than DTA + PA due to the extra cargo
load. To our delight, when we treated the cells with these constructs, we observed superior activity
of DTA-PA to DTA + PA, eliminating the possibilities of premature cleavage and DTA-PA trans-
location. Fusion of the N-terminal K5 tag further demonstrated that the single-component PA sys-
tem significantly improved the translocation of the LFN-null cargo. Another observation from these
experiments was that linker1 was consistently better than linker2 and the difference widened in
the case of K5 tagged DTA. Since it is unlikely that the short D-linker is more susceptible to cleav-
age in endosome, a more plausible explanation would be the longer and more flexible linker causes
intramolecular interaction between the cargo protein and PA, which inhibited the translocation
process. This effect would become more prominent with K5 tagged cargo due to the stronger in-
teraction between the tag and the negatively-charged cation-selective PA pore. This observation
also suggests that the linker cleavage is the rate-limiting step.
It was discovered years ago by the Collier group that fusing a stretch of basic amino acids
to the N-terminus of DTA can potentiate its PA-dependent translocation . It is believed that the
poly-lys tag is drawn by the negatively charged pore by electrostatic attraction and inserts itself
into the lumen of the pore. The cargo protein is then translocated through the pore by charge state-
dependent Brownian ratcheting process. Here we show that the covalent linkage of the cargo to
PA significantly enhanced the translocation with or without the K5 tag. Our results suggest that the
poly-lys is not enough to fully co-localize the tagged cargo with the PA prepore and it contributes
to the improved activity primarily by facilitating the initiation of translocation. Another point
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worth discussion is that since K5DTA-PA has some binding affinity to the prepore/pore and the
linker cleavage is likely the rate-limiting step, the intact K5DTA-PA will compete with free
K5DTA and as a result the potential of the single-component system was probably not fully real-
ized. In the future, we envision the system can be further improved by optimizing the linker for
endosomal cleavage and other cargos in addition to DTA will delivered using this strategy.
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3.4. Experimental
3.4.1 Synthesis and purification of peptide linkers
Fmoc-protected amino acids were purchased from ChemImpex. Peptide linker1 and
linker2 were synthesized using either manual flow peptide synthesis or automated flow peptide
synthesizer on ChemMatrix resin with a Rink amide linker as previously described26,27. The ma-
leimide was coupled on the side chain of L- or D-lysine by treating the Lys-deprotected resin with
1.5 equivalents of N-y-maleimidobutyryl-oxysuccinimide ester (GMBS, Thermo Fisher) dissolved
in DMF for 3 h. The crude peptides were cleaved by TFA/H 20 (97.5:2.5) at RT for 2 h and purified
by semi-preparative RP-HPLC with Agilent Zorbax 300SB C 18 column (9.4 x 250 mm, 5 um) at a
flow rate of 4 mL/min using the gradient of 1-31% acetonitrile over 80 min. HPLC fractions were
subsequently analyzed by LC-MS and pure ones were pooled and lyophilized (supplementary fig-
ure).
3.4.2. Protein expression and purification
All proteins were expressed in E. coli BL21 (DE3) cells from Thermo Fisher. PA[K563C]
(PAC) and K5DTA-LPSTGG were prepared from WT PA and DTA-LPSTGG respectively using
QuickChange single site-directed mutagenesis kit (Agilent). The expression of PAC was done at
New England Regional Center of Excellence/Biodefense and Emerging Infectious Diseases
(NERCE) and purified as previously described. 15g to 25g of cell pellet was resuspended in
sucrose buffer (20 mM Tris pH 8.5, 1 mM EDTA, 20% sucrose) and incubated with 5 mM MgSO 4
buffer. The supernatant was purified by an anion exchange chromatography and pure fractions
were pooled. LFN-DTA-LPSTGG (LD), DTA-LPSTGG, and K5DTA-LPSTGG in Champion
PET-His 6-SUMO vector were also expressed in E. coli BL21(DE3). The bacteria were grown at
37'C until OD reached 0.7~0.9 and induced with 0.4 mM IPTG at 30'C for 16 h. The proteins
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were purified by a HisTrap FF crude Ni-NTA column (GE) and desalted by buffer exchange. The
SUMO was cleaved by SUMO protease and removed by size exclusion chromatography.
3.4.3. Generation of single-component anthrax delivery system
Cargo proteins with C-terminal LPSTGG tag (50 uM) were first conjugated with poly-
glycine maleimide peptide linkers (1.5 mM) by a triple mutant sortase (SrtA*) 2 8 and purified by
Ni beads pull-down as previously described. 1.5 equivalents of maleimide labeled cargo protein
(30 uM) was then reacted with PAC (20 uM) in 20 mM Tris, 150 mM NaCl buffer (pH 8.5) at RT
for 1 h and the resulted mixture was loaded onto HiLoad 16/600 Superdex 200 pg size exclusion
column (GE). The fractions were analyzed by SDS-PAGE stained with Coomassie dye and the
fractions containg cargo-PA were pooled and concentrated.
3.4.4. Cell viability assays
HeLa cells were purchased from American Type Culture Collection (Manassas, VA) and
maintained in MEM supplemented with 10% at 37*C in a 5% CO2 environment. On the day prior
to treatment, the cells were seeded in a 96-well plate at a density of 5x 103 per well and allowed to
attach overnight. The next day, the cells were treated with 5-fold serial dilutions of different pro-
teins for 72 h. The cell viability was measured by CellTiter-Glo luminescent assay (Promega)
following the manufacturer's protocol. The relative viability was normalized to cells without treat-
ment (n=3).
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3.6. Appendix
3.6.1. The amino acid sequences of the PA mutants used in this study
PA[K563C] (PAC)
MEVKQENRLLNESESSSQGLLGYYFSDLNFQAPMVVTSSTTGDLSIPSSELENIPSENQYF
QSAIWSGFIKVKKSDEYTFATSADNHVTMWVDDQEVINKASNSNKIRLEKGRLYQIKIQ
YQRENPTEKGLDFKLYWTDSQNKKEVISSDNLQLPELKQKSSNSRKKRSTSAGPTVPDR
DNDGIPDSLEVEGYTVDVKNKRTFLSPWISNIHEKKGLTKYKSSPEKWSTASDPYSDFEK
VTGRIDKNVSPEARHPLVAAYPIVHVDMENIILSKNEDQSTQNTDSETRTISKNTSTSRTH
TSEVHGNAEVHASFFDIGGSVSAGFSNSNSSTVAIDHSLSLAGERTWAETMGLNTADTA
RLNANIRYVNTGTAPIYNVLPTTSLVLGKNQTLATIKAKENQLSQILAPNNYYPSKNLAPI
ALNAQDDFSSTPITMNYNQFLELEKTKQLRLDTDQVYGNIATYNFENGRVRVDTGSNW
SEVLPQIQETTARIIFNGKDLNLVERRIAAVNPSDPLETTKPDMTLKEALKIAFGFNEPNG
NLQYQGKDITEFDFNFDQQTSQNICNQLAELNATNIYTVLDKIKLNAKMNILIRDKRFHY
DRNNIAVGADESVVKEAHREVINSSTEGLLLNIDKDIRKILSGYIVEIEDTEGLKEVINDR
YDMLNISSLRQDGKTFIDFKKYNDKLPLYISNPNYKVNVYAVTKENTIINPSENGDTSTN
GIKKILIFSKKGYEIG
PA[F427A, K563C] (PACA)
MEVKQENRLLNESESSSQGLLGYYFSDLNFQAPMVVTSSTTGDLSIPSSELENIPSENQYF
QSAIWSGFIKVKKSDEYTFATSADNHVTMWVDDQEVINKASNSNKIRLEKGRLYQIKIQ
YQRENPTEKGLDFKLYWTDSQNKKEVISSDNLQLPELKQKSSNSRKKRSTSAGPTVPDR
DNDGIPDSLEVEGYTVDVKNKRTFLSPWISNIHEKKGLTKYKSSPEKWSTASDPYSDFEK
VTGRIDKNVSPEARHPLVAAYPIVHVDMENIILSKNEDQSTQNTDSETRTISKNTSTSRTH
TSEVHGNAEVHASFFDIGGSVSAGFSNSNSSTVAIDHSLSLAGERTWAETMGLNTADTA
RLNANIRYVNTGTAPIYNVLPTTSLVLGKNQTLATIKAKENQLSQILAPNNYYPSKNLAPI
ALNAQDDASSTPITMNYNQFLELEKTKQLRLDTDQVYGNIATYNFENGRVRVDTGSNW
SEVLPQIQETTARIIFNGKDLNLVERRIAAVNPSDPLETTKPDMTLKEALKIAFGFNEPNG
NLQYQGKDITEFDFNFDQQTSQNICNQLAELNATNIYTVLDKIKLNAKMNILIRDKRFHY
DRNNIAVGADESVVKEAHREVINSSTEGLLLNIDKDIRKILSGYIVEIEDTEGLKEVINDR
YDMLNISSLRQDGKTFIDFKKYNDKLPLYISNPNYKVNVYAVTKENTIINPSENGDTSTN
GIKKILIFSKKGYEIG
*The mutated residues are highlighted in red.
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3.6.2. The amino acid sequences of the LFN-DTA-LPSTGG, DTA-LPSTGG, and K5DTA-
LPSTGG
LFN-DTA-LPSTGG (LD)
AGGHGDVGMHVKEKEKNKDENKRKDEERNKTQEEHLKEIMKHIVKIEVKGEEAVKKE
AAEKLLEKVPSDVLEMYKAIGGKIYIVDGDITKHISLEALSEDKKKIKDIYGKDALLHEH
YVYAKEGYEPVLVIQSSEDYVENTEKALNVYYEIGKILSRDILSKINQPYQKFLDVLNTIK
NASDSDGQDLLFTNQLKEHPTDFSVEFLEQNSNEVQEVFAKAFAYYIEPQHRDVLQLYA
PEAFNYMDKFNEQEINLSLEELKDQRSGRELERGADDVVDSSKSFVMENFSSYHGTKPG
YVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNKYDAAGYSVDNENPLSGKAGGVVKV
TYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPFAEG
SSSVEYINNWEQAKALSVELEINFETRGKRGQDAMYEYMAQASAGNRLPSTGGHHHHH
DTA-LPSTGG
ADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNK
YDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQ
VGTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDA
MYEYMAQASAGNRLPSTGGHHHHHH
K5DTA-LPSTGG
AKKKKKADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKG
FYSTDNKYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSL
TEPLMEQVGTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETR
GKRGQDAMYEYMAQASAGNRLPSTGGHHHHHH
*The polylysine tag is highlighted in red. The N-terminal alanine was introduced to facilitate
SUMO cleavage based on the manufacturer's protocol.
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Figure 3.6.1. LC-MS traces and mass analyses of the peptide linkers used in this study. D-
amino acids are indicated by the lowercase letters. About 200 ng of each peptide was injected into
Zorbax 300SB C3 column with a method of 5-65% acetonitrile over 5 minutes.
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Figure 3.6.2. LC-MS deconvoluted masses of LD, LD-linkerl, and LD-linker2. The peptide
linkers were conjugated to LD as described in the manuscript. 200 ng of each protein was injected
into Zorbax 300SB C3 column with a method of 5-65% acetonitrile over 15 minutes. The TIC peak
was integrated and the mass was deconvoluted using maximum entropy algorithm.
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Figure 3.6.3. LC-MS deconvoluted masses of DTA-LPSTGG, DTA-linkerl, and DTA-
linker2. The peptide linkers were conjugated to DTA-LPSTGG as described in the manuscript.
200 ng of each protein was injected into Zorbax 300SB C3 column with a method of 5-65% ace-
tonitrile over 15 minutes. The TIC peak was integrated and the mass was deconvoluted using max-
imum entropy algorithm.
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Figure 3.6.4. LC-MS deconvoluted masses of K5DTA-LPSTGG, K5DTA-linkerl, and
K5DTA-linker2. The peptide linkers were conjugated to K5DTA-LPSTGG as described in the
manuscript. 200 ng of each protein was injected into Zorbax 300SB C3 column with a method of
5-65% acetonitrile over 15 minutes. The TIC peak was integrated and the mass was deconvoluted
using maximum entropy algorithm.
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Figure 3.6.5. Preparation of K5DTA-PA conjugates analyzed by SDS-PAGE. K5DTA with
either linker1 or linker2 was conjugated to PAC as described in the methods section. The resulted
crude reaction mixture was separated by size exclusion column. The fractions were run on SDS-
PAGE and stained by Coomassie blue. The pure fractions were pooled, concentrated, QCed by
LC-MS, and stored in -80'C.
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Figure 3.6.6. Preparation of K5DTA-PAA conjugates analyzed by SDS-PAGE. K5DTA with
either linker 1 or linker2 was conjugated to PACA as described in the methods section. The resulted
crude reaction mixture was separated by size exclusion column. The fractions were run on SDS-
PAGE and stained by Coomassie blue. The pure fractions were pooled, concentrated, QCed by
LC-MS, and stored in -80'C.
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Figure 3.6.7. LC-MS deconvoluted masses of PAC, LD-linkerl-PA, and LD-linker2-PA. LDs
with different linkers were conjugated to PAC as described in the manuscript. 200 ng of each
protein was injected into Zorbax 300SB C3 column with a method of 5-65% acetonitrile over 15
minutes. The TIC peak was integrated and the mass was deconvoluted using maximum entropy
algorithm.
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Figure 3.6.8. LC-MS deconvoluted masses of PACA and LD-linkerl-PAA. PACA glutathione
adduct (+305.43 Da) was also found in this batch of PACA. However, the adduct did not react
with LD-linkerl due to the capped cysteine as expected. LD-linkerl was conjugated to PACA as
described in the manuscript. 200 ng of each protein was injected into Zorbax 300SB C3 column
with a method of 5-65% acetonitrile over 15 minutes. The TIC peak was integrated and the mass
was deconvoluted using maximum entropy algorithm.
160
PA[K563C] (PAC)
Obs. 82780.63
Calc. 82783. 52
75000 8'000 85'000 90'000 9--000 1iobooo 10000 11booo
Deconvoluted Mass (Da)
DTA-linkerl -PA
Obs. 104587.80
Calc. 104567.38
76000 86000 8'000 96000 96000 1obooo 10000 11booo
Deconvoluted Mass (Da)
DTA-linker2-PA
Obs. 105737.14
Calc. 105734.78
75000 86000 8000 96'000 96000 10booo 106000 11OOO
Deconvoluted Mass (Da)
Figure 3.6.9. LC-MS deconvoluted masses of PAC, DTA-linkerl-PA, and DTA-linker2-PA.
DTAs with different linkers were conjugated to PAC as described in the manuscript. 200 ng of
each protein was injected into Zorbax 300SB C3 column with a method of 5-65% acetonitrile over
15 minutes. The TIC peak was integrated and the mass was deconvoluted using maximum entropy
algorithm.
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Figure 3.6.10. LC-MS deconvoluted masses of PAC, K5DTA-linkerl-PA, and K5 DTA-
linker2-PA. K5DTAs with different linkers were conjugated to PAC as described in the manu-
script. 200 ng of each protein was injected into Zorbax 300SB C3 column with a method of 5-65%
acetonitrile over 15 minutes. The TIC peak was integrated and the mass was deconvoluted using
maximum entropy algorithm.
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Figure 3.6.11. LC-MS deconvoluted masses of PACA, K5DTA-linkerl-PAA, and K5DTA-
linker2-PAA. K5DTAs with different linkers were conjugated to PACA as described in the man-
uscript. 200 ng of each protein was injected into Zorbax 300SB C3 column with a method of 5-
65% acetonitrile over 15 minutes. The TIC peak was integrated and the mass was deconvoluted
using maximum entropy algorithm.
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